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3 Introduction 
In chemicals risk assessment frameworks, the default approach is to assess external intake from 
different sources of exposure and via different routes of exposure. They are often assessed 
separately. This approach includes various uncertainties and often overestimates the real uptake 
since default, conservative estimates are used e.g. for the absorption of the chemical. At the same 
time, actual (real life) exposure may be underestimated by not taking into account that exposure to 
a chemical substance may occur from different sources, which may fall under separate legislative 
frameworks. Examples are triclosan that is used in biocidal products as well as in consumer 
products and importantly, most if not all chemicals that are produced by workers where at the 
same time these workers may be exposed as part of the general population. In some cases, other 
tools to assess exposure via all possible routes may be insufficient; an example is occupational 
exposure via hand-to-mount exposure, which has been shown to occur for example in the case of 
many metals, like lead, through contaminated hands. Without biomonitoring, exposure in these 
cases could become severely underestimated. 
Human Biomonitoring (HBM) is an important tool to survey the real life body burden – or internal 
exposure – of humans resulting from ‘total’ exposure to chemicals via different routes (lung, skin, 
digestive tract) and ‘via’ different legislative frameworks on chemicals. By providing more accurate 
data on actual body burdens (internal exposure), inclusion of HBM data could improve human 
health risk assessment for both the general population (exposure via air, consumer products, 
drinking water and food) as well as for workers (exposure via inhalation and/or skin) separately or 
as part of the population.  
HBM could be helpful in other areas as well, demonstrating for example increased blood levels 
because of accumulation of a chemical in the body following repeated exposure. In many 
frameworks, human absorption, distribution, metabolism, and excretion (ADME) and toxicokinetics 
data including the body half-life are not necessarily required for the safety assessment of the 
chemical. HBM has also been used to showcase that interindividual differences with respect to 
respiratory ventilation and use of personal protection equipment are reflected in internal exposure. 
These differences are not observed using ambient air monitoring. In addition, by using HBM data it 
could be possible to bridge with new conceptual developments such as AOPs (adverse outcome 
pathways) and to investigate direct linkages between internal exposure and the onset of AOPs 
resulting in adverse health effects.  
Naturally, HBM has also limitations including the fact that it often gives only a snap shot of 
exposure due to the assessment of single time points, often metabolites and not the parent 
compounds are measured, and exposure biomarkers are only proxies measured in easily 
accessible tissues and fluids and are not necessarily the concentrations at target organs. In 
addition, total body burden may be in some cases difficult to link to specific exposure sources. 
These limitations need to be recognised when interpreting biomonitoring data. 
Although the past few years have shown good examples on the use of HBM in the risk assessment 
of chemicals, there is still quite some work to improve its use in risk assessment and human impact 
assessment. As a matter of fact, the US National Academies of Sciences, Engineering and 
Medicine in a recently released report on ”Using 21st Century Science to Improve Risk-Related 
Evaluations” (US NAS, 2017), lays out recommendations to incorporate the emerging science into 
risk-based evaluations. In that capacity, HBM is described as an essential tool allowing for 
advances in exposure science and epidemiology.  
Therefore, the HBM4EU project aims to deliver European wide quantitative information on levels of 
internal exposure biomarkers and effect biomarkers. Using thousands of individually linked pieces 
of information on exposure and health-effect biomarkers, the aim is to establish ‘internal exposure-
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health effect relationships’. If successful, this will provide molecular epidemiological (= legislative 
framework independent) knowledge that could be used alongside the classical toxicological, 
regulatory framework-driven risk assessment. Moreover and at the same time, using the newly 
developed ‘internal exposure - health effect relationships’, health impact assessment (HIA) of 
chemicals would become more feasible. Altogether, improvement and the combined use of human 
health risk assessment and HIA will provide the necessary tools for a significant step forward in the 
important domain of chemicals risk management. 
In order to achieve this goal and to provide strong anchoring to current risk assessment practices, 
in this report, the current use of human biomonitoring in risk assessment of chemicals has been 
evaluated. Firstly, different global (World Health Organization (WHO), Food and Agriculture 
Organization of the United States (UN FAO)) and regional (EU) risk assessment schemes were 
screened for information on HBM including the availability of guidance on how to use HBM in risk 
assessment.  
In addition, a survey was held to collect information from national regulatory risk assessors on their 
day to day risk assessment practices, the use of HBM, and obstacles and challenges related to the 
use of HBM (in EU, European non-EU as well as non-European countries).  
Finally, we have presented good examples on the advanced use of human biomonitoring of a few 
selected chemicals from the HBM4EU prioritised substance groups. Based on these data some 
proposals are provided for the better inclusion of HBM in human risk assessment and health 
impact assessment. 
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4 Overview on risk assessment and health impact 
assessment schemes 
 International risk assessment schemes 
International risk assessment schemes such as from WHO and UN FAO provide a wealth of 
information and concrete guidance on how to perform risk assessment. In many parts and 
countries of the world, actual and concrete risk assessment for a specific chemical in the sense of 
a concrete risk prediction (i.e. actual exposure divided by a safe level such as an acceptable daily 
intake (ADI)) is a national prerogative. International ‘risk assessment’ schemes do propose 
however safe exposure levels such as TDI’s or linked to this, MRL’s (maximum residue levels). By 
doing so, these international bodies support especially those countries for which national or 
regional expertise and capacity to do so is limited. By this, they also enable international 
comparability of feed and food risk assessments and thereby promote fair practices in food and 
feed trade. Another reason is that concrete risk predictions require adequate exposure levels and 
these are often country-specific. 
 WHO 
Under WHO/International Programme on Chemical Safety (IPCS) umbrella, the paradigm of risk 
assessment process begins with problem formulation and includes four additional steps: 1) hazard 
identification, 2) hazard characterisation, 3) exposure assessment and 4) risk characterisation 
(IPCS, 2004) - see Table 1. A full description of the concepts presented in the table may be found in 
chapter 3 of WHO Environmental Health Criteria (EHC) 239 (IPCS, 2009a).  
Table 1: WHO/IPCS Paradigm of Risk Assessment 
Step Description Content 
Problem formulation Establishes de scope and 
objectives of the assessment 
Defining the question  
Prior knowledge 
Desired outcomes 
Hazard identification Identifies the type and nature of 
the adverse health effects 
Human studies 
Animal-based toxicology studies 
In vitro toxicology studies 
Structure-activity studies 
Hazard 
characterization 
Quantitative or qualitative 
description of the inherent 
properties of an agent having 
properties to cause adverse 
health effect 
Selection of critical dataset 
Modes/mechanism of action 
Kinetic variability 
Dynamic variability 
Dose-response for critical effect 
Exposure assessment Evaluation of the concentration or 
amount of a particular agent that 
reaches the target population 
Magnitude  
Frequency 
Duration 
Route 
Extent 
Risk characterization Advice for decision-making Probability of occurrence 
Severity 
Given population 
Uncertainties 
EHC 214 (IPCS, 2000) refers that human health risk assessments of chemicals can be performed 
to evaluate past, current and even future exposures to any chemical found in air, soil, water, food, 
consumer products or other materials and that can be quantitative or qualitative in nature. Human 
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health risk assessment for chemical hazards is a means of integrating the components of the 
environmental health chain in a manner that is useful for analysis and management of chemical-
mediated risks. 
In IPCS, 2004, human health risk assessment is described as a process intended to estimate the 
risk to a given target organism, system or (sub)population, including the identification of attendant 
uncertainties, following exposure to a particular agent, taking into account the inherent 
characteristics of the agent of concern as well as the characteristics of the specific target system. 
The WHO Human Health Risk Assessment Toolkit: Chemical Hazards (IPCS, 2010) has been 
developed to support especially developing countries and countries with economies in transition in 
the management of chemical risks. It is a very practical tool, which is meant to provide its users the 
basic information needed for the assessment of chemical risks. It gives guidance to identify, 
acquire and use the information needed to assess chemical hazards, exposures and the 
corresponding health risks in their given health risk assessment contexts at local and/or national 
levels. 
Human biomonitoring in WHO risk assessment scheme 
WHO/IPCS risk assessment scheme refers that besides the use of traditional exposure assessment, 
the use of biological markers represents another method to evaluate human exposure to a chemical, 
and that the selection of sampling media depends on the contaminant of interest, the pattern of 
exposure, the timing of exposure, the population studied, ease of collection and storage and 
participant burden. Human biological monitoring is frequently considered invasive; however, several 
media that can be collected in a non-invasive manner are available for exposure assessment. Blood 
and urine, as well as exhaled breath and saliva, can be used to document recent exposures; past 
exposure can be evaluated using blood and urine, as well as keratinized tissues (hair and nails), 
ossified tissue (teeth and bone), adipose tissue and breast milk. Adipose tissue and bone can also 
represent future sources of internal exposure. Further information on biomarkers of exposure is 
available in IPCS (1993a, 2000, 2001b) (see also Table 2). 
Table 2: Some WHO sources of guidance on biomarkers 
Document title Reference 
Biomarkers and risk assessment: concepts and principles 
(EHC 155) 
IPCS (1993a) 
Human exposure assessment (EHC 214) IPCS (2000) 
Biomarkers in risk assessment: validity and validation 
(EHC 222) 
IPCS (2001b) 
In WHO (2010), it is mentioned that the greatest uncertainties in risk assessment almost always 
arise from inadequate exposure data, inadequate understanding of mechanisms of toxicity, and 
insufficient understanding of the exposure-dose-response pathway (Becking, 1995; McClellan, 
1995). Two additional factors that can lead to uncertainties in risk assessment include mixed or 
multiple exposures implicated in the disease pathway, and variability of both exposures and 
responses within and between individuals. 
In specific guidance on biomarkers, e.g. IPCS (1993a) “Biomarkers and risk assessment: concepts 
and principles” (EHC 155), the relevance of using the different types of biomarkers in the different 
phases of the risk assessment process are discussed in specific sections of the document: 
 Biomarkers of exposure can be used to confirm and assess the exposure of individuals or 
populations to a particular substance, providing a link between external exposures and 
internal dosimetry. 
 Biomarkers of effect can be used to document either preclinical alterations or adverse 
health effects elicited by external exposure and absorption of a chemical. Thus the linkage 
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of biomarkers between exposure and effect contributes to the definition of dose-response 
relationships.  
 Biomarkers of susceptibility help elucidate the degree of the response to exposure elicited 
in individuals.  
It is also highlighted in this document that the biomarkers in health risk assessment 
(measurements within the context of "biological monitoring") have been used to assess worker 
exposure and, in clinical settings, to evaluate the administration of therapeutic agents. These 
measurements, or biomarkers, provide the critical link between chemical exposure, internal dose 
and health impairment, and are of value in assessment of risk. However, it is said that there is a 
need to identify and validate for each organ system the characteristic parameter(s) that are 
indicative of induced dysfunction, clinical toxicity or pathological change, as well as to establish the 
specificity and sensitivity of each biomarker and its method of measurement (e.g. biological 
markers of effect and markers for susceptibility – please see figure Figure 1). 
 
Figure 1: Rationale for using biomarkers to assess risk (from Schulte&Waters, 1999) 
In IPCS (2001b) Biomarkers in risk assessment: validity and validation (EHC 222), biomarkers for 
risk assessment were considered and a framework for selecting and validating biomarkers was 
developed (Table 3). How the three types of biomarkers, of exposure, of effect and of 
susceptibility, could be validated for research and be used in risk assessments. It was considered 
that valid biomarkers can lead to biologically based risk assessments although there have been 
few cases where validated biomarkers have been used in quantitative risk assessments. Also, 
that the lack of validation of most biomarkers of intermediate effect was probably the most critical 
impediment to the broad use of biomarkers in risk assessment.  
Table 3: Characteristics of valid biomarkers 
Biomarker type Characteristic of validity 
Exposure Consistently linked with exposure at relevant levels of exposure with 
confounding and background exposures assessed* 
Effect Consistently linked with increased risk with confounding and effect 
modifying factors assessed  
Susceptibility Can distinguish subgroups at risk given specific exposure 
 
*Biomarkers of exposure may also be validated by establishing a constant link to an adverse health 
effect or to the concentration of the chemical in the target organ. 
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The main conclusions from this document include: 
 Validation of biomarkers for research and risk assessment requires both laboratory and 
epidemiological studies. 
 Successful use of biomarker data implies an understanding of mechanisms. The 
incorporation of mechanistic data in risk assessment is certainly important, but risk 
assessments and regulations should not wait for the development of mechanistic data nor 
should uncertainty about mechanism be used to block public health action. 
 The contribution of biomarkers of susceptibility has great potential but has yet to be realised 
on a large scale in quantitative risk assessment. 
 There is a need for a long-term commitment to the assessment of the validity of biomarkers 
for risk assessment, environmental health research and public health practice. Introduction 
of new and validated methods based upon new technologies to study biomarkers of 
exposure, effect and susceptibility at the different levels of the risk management process will 
be of great assistance to risk assessors. 
Recommendations were made especially for research: 
 to develop more incisive biomarkers to fill in the gaps in the continuum of events from 
environmental exposure to clinical disease expression, taking advantage of new, high-
throughput technologies 
 to study the genetic basis for different susceptibilities toward environmental exposures and 
how this exposure influences the phenotype 
 to develop and use bioinformatics and advanced statistical methods to fully utilise existing 
and newly generated data 
 
Also WHO Risk assessment toolkit (IPCS, 2010), meant for use especially in developing countries, 
recognises the role of human biomonitoring in chemical risk assessment and refers to specific 
WHO guidance on exposure assessment and the use of human biomonitoring data in risk 
assessment. In addition, under the umbrella of the WHO Chemical Risk Assessment Network, 
WHO organised a workshop on human biomonitoring to support chemical risk assessment in 
Bangkok, Thailand in November 2016 (http://www.who.int/ipcs/network/BKK2016/en/). The 
workshop was intended to provide a forum to exchange information and knowledge and facilitate 
future collaboration related to HBM in chemical risk assessment, especially in low resource 
settings. 
HBM4EU priority substances evaluated by WHO 
WHO has evaluated a wide range of chemicals in the past. These evaluations have been 
published under WHO EHC series or as Concise International Chemical Assessment Documents 
(CICADs). Latest CICAD published by this far is on hexavalent chromium, which is one of the 
priority compounds under HBM4EU (WHO, 2013). It describes some data on the human 
biomonitoring of chromium at the workplaces using urinary total chromium as an unspecific marker 
for the hexavalent chromium exposure. Sample risk characterisation is made for workers for lung 
cancer using air monitoring data for exposure assessment. 
 WHOPES 
WHO pesticides evaluation scheme (WHOPES) has published generic risk assessment models to 
be used in the risk assessment of insecticides used for indoor residual spraying, larviciding, space 
spraying, treatment of mosquito nets and aircraft disinfection 
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(http://www.who.int/whopes/guidelines/en/). The described models are meant as first tier models to 
be used in the approval of new formulations and should be refined by using more advanced 
models or measured data if needed. No reference to the use of human biomonitoring data in the 
risk assessment or post-approval surveillance has been made, except regarding the possible use 
of human data on acetylcholinesterase inhibition in the hazard and dose-response assessment of 
organophosphates. 
 FAO 
The UN FAO has published, in 2013, a document entitled “GUIDELINES ON THE APPLICATION 
OF RISK ASSESSMENT FOR FEED” (FAO 2013) that provides a description on the FAO risk 
assessment practices.  
Considering that the presence of hazards in the feed of food-producing animals may imply 
subsequent transfer of hazards to edible products, the document provides a guidance for feed and 
feed ingredients risk assessment by governments in accordance with Codex principles for risk 
analysis. Risk assessment under the codex risk analysis framework is described to include: 
 identification of a food safety problem arising from feed;  
 establishment of a risk profile;  
 ranking of the hazard for risk assessment and risk management priority (for further details 
see EFSA 2013);  
 determination of a risk assessment policy for the conduct of the risk assessment;  
 definition of the output form of the risk assessment;  
 commissioning of the risk assessment, and 
 consideration of the possible results of the risk assessment. 
Human biomonitoring in FAO risk assessment scheme 
The steps involved in Risk assessment procedure are enunciated in this document and do not 
account explicitly for HBM. However, international programs such as the WHO Global Environment 
Monitoring System (GEMS/Food), the Joint FAO/WHO International Food Safety Authorities 
Network (INFOSAN), and other reliable rapid alert systems, and industry self-monitoring programs 
are referred as important sources of useful information. In addition, the document refers that further 
information is provided in the WHO Principles and Methods for the Risk Assessment of Chemicals 
in Food.  
In this document, human exposure assessment is seen as the qualitative and/or quantitative 
evaluation of the likely intake of the hazard(s) via food, while the aim of the exposure assessment in 
feed risk assessment is to estimate the level or prevalence of hazard(s) in edible product(s) after 
transfer from feed. Subsequently, these estimated levels of hazard in edible product arising from 
feed are used as input for human exposure assessment.  The feed exposure assessment should 
result in the determination of the predicted level or prevalence of a hazard in edible product. This 
result is then incorporated as a starting point in the human exposure assessment for food. The 
evaluation of the human exposure to the hazard should be done using relevant foods and food 
groups and/or specific human populations to account for feed as a source of exposure, (e.g. by 
modelling). 
HBM4EU priority substances evaluated by FAO 
In the document, the hazards in feed can include biological and chemical agents (such as "heavy 
metals", dioxins, excessive levels of pesticides, veterinary drugs and additives), radionuclides and 
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other undesirable substances. Biotransformation products present in edible products also need to 
be considered.  
A recent paper examined 564 feed samples over a period of five years (2010-2015) collected by 
Texas Feed and Fertilizer Control Service and provided a comprehensive analysis of heavy metals 
during the prescribed time period and ingredient/finished feed type to facilitate risk assessment and 
implementation of risk management techniques (Dai et al., 2016).  
Another paper described the review of chemical contaminants in byproducts in animal feed during 
1998-2009 in Denmark (Mortensen et al., 2014). Also, several samples of citrus pulp and dried 
distillers grains with solubles were additionally collected for analysis and risk assessment. The levels 
of contaminants in the samples from the official control were below maximum limits from EU 
regulations with only a few exceptions in the following groups; dioxins and dioxin-like 
polychlorobiphenyls (PCBs) in fish-containing byproducts and dioxins in vegetable and animal fat, 
hydrogen cyanide in linseed, and cadmium in sunflowers (Mortensen et al., 2014).. 
A European review about dioxins and PCBs in feed and food is described in another paper 
suggesting that fish, meat and dairy products appeared to be the highest contributing food groups to 
dietary exposure (Malisch and Kotz, 2014). 
 EU Risk assessment schemes 
 EU Chemicals legislation (REACH) 
Regulation (EC) No 1907/2006 on the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) requires from producers and importers to register all substances placed on 
the EU market above 1 tonne per year1. REACH obliges registrants who markets a substance at 
≥10 t/year to conduct a chemical safety assessment (i.e. risk assessment), and provide it to the 
European Chemicals Agency (ECHA) as part of the Registration dossier. Both the environmental 
and health risk assessments are based on the fundamental assumption that risk is a function of 
hazard and exposure. If a hazard is identified, a relationship between exposure (dose) and the 
effect is sought, which can be used to estimate whether a risk exists and determine whether risk 
management measures are required. 
Description 
REACH introduced the concept of Derived No-Effect Level (DNEL), defined as the level of a 
substance above which a human should not be exposed. DNELs must be derived for all hazardous 
substances placed on the market in quantities exceeding 10 tonnes per year and should reflect 
route, duration and frequency of exposure. DNELs should be derived for occupational settings, 
consumer use, and for the general population for indirect exposure via the environment (Boogaard 
et al., 2011). 
The standard methodology involves setting a point of departure (POD), which is a modified dose 
descriptor, usually based on a no-observed-adverse-effect level (NOAEL) from an animal study. To 
the POD a series of default assessment factors is applied to compensate for variations as well as 
uncertainties with regard to the differences of sensitivity to the substance for which the DNEL is 
                                               
1 EC, Regulation (EC) No. 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, 
Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 
1999/45/EC and repairing Council Regulation (EEC) No. 793/93 and Commission Regulation (EC) No. 1488/94 as well as Council 
Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/ 105/EC and 2000/21/EC, vol. 1907/2006, 2006. 
Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1907  
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derived. Substance-specific data can be used when available to refine the default factors 
recommended in the guidance. When an indicative or binding occupational exposure limit (IOEL or 
BOEL) has been adopted in the EU following a recommendation report prepared by the Scientific 
Committee of Occupational Exposure Limits (SCOEL) (see section 4.2.5) or when there is an 
adopted occupational exposure limit set by national authority in one of the Member states, these 
can be used as DNEL values for occupational settings, provided they are documented and health-
based. As described in section 4.2.4 BOELs usually take socio-economic considerations into 
account, which may prevent their use as such as DNELs. 
The risk assessment is more complicated for effects where there is no identified threshold 
concentration, particularly for genotoxic carcinogens. In these cases, a stringent level of 
acceptable risk is established, called the Derived Minimal Effect Level (DMEL). 
The conditions of exposure are defined in REACH by the use of exposure scenarios, which 
comprise a set of operational conditions (e.g. process temperature, concentration of substance) 
and risk management measures (RMM) (e.g. local exhaust ventilation, protective equipment). For 
each exposure scenario, the assessor makes an estimate of the exposure, using measured or 
calculated data. 
When risk assessment is performed, DNELs or DMELs are compared to exposure levels to derive 
a risk characterisation ratio (RCR). If the exposure estimate is equal to or higher than the DNEL or 
DMEL, the substance will be of concern with regard to the population considered. The assessor 
may decide that additional information, either concerning exposure or toxicity, is necessary to 
refine the chemical risk assessment. If the exposure cannot be controlled below the DNEL or 
DMEL, then the use pattern given in the exposure scenario is designated as a ‘use advised 
against’ which is recorded in the safety data sheet. 
Human biomonitoring in REACH 
For the characterisation of the dose-response relationship for human health, DNELs may be 
expressed as internal exposure biomarker values, applying to the substances for which internal 
exposure data are available and have been reliably associated with effects. In general, when both 
internal exposure (human biomonitoring) and external exposure monitoring data are available, and 
effects data corresponding to both types of exposure data are available, the most appropriate 
and/or reliable data/method should be used for setting the DNEL. When deriving an internal 
biomarker DNEL, it has to be clearly indicated that it is a biomarker value, e.g., by mentioning 
“biomarker” as subscript to DNELbiomarker (ECHA, 2008a). 
However, REACH requirements do not include any incentive to understand the relationship 
between internal exposure biomarkers of the substance and effects. It is also noted that 
toxicokinetic studies or measurement of the internal dose of a substance and/or its metabolites is 
generally not part of the regulatory toxicological tests. The development of knowledge on the 
relationship between effects and the internal doses of substances is therefore not common practice 
in the Registration dossiers. Unfortunately, REACH IUCLID system where dossier submitters have 
to file substance information contains no field reserved for a DNELbiomarker. This does not encourage 
registrants to consider the possibility to set a DNELbiomarker. 
Human biomonitoring, which integrates all exposures regardless the route of exposure, is most 
helpful in: 1) the actual exposure assessment for complex scenarios and 2) the validation that 
operational conditions and RMM considered in the exposure scenarios result in safe exposures. 
However, guidance on how to use HBM in risk characterisation and management is limited 
(Boogaard et al., 2011; ECHA, 2008a). 
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The authorisation procedure aims to assure that the risks from Substances of Very High Concern 
(SVHC)2 are properly controlled and that these substances are progressively replaced by suitable 
alternatives while ensuring the good functioning of the EU internal market. After a two-step 
regulatory process, SVHCs may be included in the Authorisation List (Annex XIV) and become 
subject to authorisation3. These substances cannot be placed on the market or used after a given 
date, unless an authorisation is granted for their specific use, or the use is exempted from 
authorisation. SVHC are substances with a serious hazard profile and it is generally expected in 
the context of applications for authorisation that the exposure is not only modelled but also 
characterised by some representative measured data. HBM, on its own or in conjunction with 
monitoring data, can therefore be used in the authorisation process to demonstrate that the RMM 
in place are sufficient to appropriately control or minimise the risks. It may also validate a reduction 
of exposure when new RMM or changes in operational conditions have been put in place. HBM is 
particularly relevant when dealing with substances with systemic effects and when significant 
absorption is expected through different routes of exposure (e.g., dermal and inhalation routes).  
Occupational human biomonitoring can also be required on an occasional or regular basis as a 
condition to grant authorisations. Examples in which occupational biomonitoring has been set as a 
condition for authorisation are available as ECHA’s Risk Assessment Committee (RAC) opinions 
on authorisation for example for trichloroethylene (ECHA, 2015a) and 4,4’-methylenedianiline 
(MDA) (ECHA, 2017a). Additionally, ECHA document “How to apply for authorisation“(ECHA, 
2016) also advices the applicants that when estimating worker exposure, biomonitoring is an 
important resource for the measured exposure dataset. In the same document there are examples 
of applications where human biomonitoring was used to clarify and demonstrate 
representativeness of exposure data.  
The restriction procedure is a tool to protect human health and the environment from unacceptable 
risks posed by chemicals4. Restrictions may limit or ban the manufacture, placing on the market or 
use of a substance. It can apply to any substance on its own, in a mixture or in an article, including 
those that do not require registration. It can also apply to imports.  
In the restriction process, human biomonitoring is used either as a basis or as supportive to the 
exposure assessment in the characterisation of an unacceptable risk that needs to be managed 
through a proposed restriction. HBM data could also be used to illustrate the impact or 
effectiveness of the restriction (i.e. reduction of the risks to human health of combined exposure to 
the substance), which is helpful to develop the benefit-cost analyse. 
To be useful for risk management however, human biomonitoring data needs to be easily 
accessible, comprehensive, harmonised, recent and representative for the targeted population. 
However, whilst human biomonitoring data integrates all exposures, HBM studies have limited 
capability in identifying the sources of exposure. Exposure modelling has been shown to be useful 
to better characterise the contributing sources of exposure and strengthen the demonstration that a 
proposed restriction will indeed reduce sources of exposure that contribute significantly to the risks 
(see example of the restriction dossier on 4 phthalates, section 5.2.1).  
                                               
2 Substances with the following hazard properties may be identified as SVHCs: 1) Substances meeting the criteria for classification as 
carcinogenic, mutagenic or toxic for reproduction category 1A or 1B in accordance with Commission Regulation (EC) No 1272/2008 
(CMR substances) ; 2) Substances which are persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative 
(vPvB) according to REACH (Annex XIII) ; 3) Substances identified on a case-by-case basis, for which there is scientific evidence of 
probable serious effects that cause an equivalent level of concern as with CMR or PBT/vPvB substances 
3 Substances included in Annex XIV of REACH (“Authorisation  list”) are available from : https://echa.europa.eu/fi/recommendation-for-
inclusion-in-the-authorisation-list 
Substances included on the Candidate list for Authorisation are available from: https://echa.europa.eu/candidate-list-table 
4 Substances restricted under REACH (Annex XVII) are available from: https://echa.europa.eu/fi/substances-restricted-under-reach 
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HBM4EU priority substances evaluated under REACH: 
Several HBM4EU priority substances have been recently evaluated under REACH regulation. 
These are listed in the following table 4. 
Table 4: HBM4EU priority substances evaluated under REACH 
Substance 
group 
Substance CAS 
Number 
Evaluation under REACH RA 
scheme 
Use of 
HBM data 
Phthalates DEHP 
Bis(2-
ethylhexyl) 
phthalate 
117-81-7 SVHC requiring authorisation No  
Application for Authorisation on 
Formulation of recycled soft PVC 
containing DEHP in compounds and 
dry-blends (ECHA 2014a) 
Yes 
Restriction in toys & childcare 
articles (ECHA 2017b) 
Yes 
BBP 
Benzyl Butyl 
phthalate 
85-68-7 SVHC requiring authorisation No 
Restriction in toys & childcare 
articles (ECHA 2017b) 
Yes 
DBP 
Di butyl 
phthalate 
84-74-2 SVHC requiring authorisation No 
Application for Authorisation for DBP 
used as an absorption solvent in a 
closed system in the manufacture of 
maleic anhydride (ECHA 2014b) 
Yes 
Restriction (toys & childcare articles) 
(ECHA 2017b) 
Yes 
DIBP 
Diisobutyl 
phthalate 
84-69-5 SVHC requiring authorisation No 
Restriction in toys & childcare 
articles (ECHA 2017b) 
Yes 
DINP  
Diisononyl 
phthalate 
28553-12-
0 
Restriction (toys & childcare articles) No 
DIDP 
Diisodecyl 
phthalate 
26761-40-
0 
DNOP 
Di-n-octyl 
phthalate 
117-84-0 
DPP  
Dipentyl 
phthalate 
131-18-0 SVHC included on the candidate list 
for authorisation 
No 
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Substance 
group 
Substance CAS 
Number 
Evaluation under REACH RA 
scheme 
Use of 
HBM data 
DIPP  
Diisopentyl 
phthalate 
605-50-5 SVHC included on the candidate list 
for authorisation 
No 
Bis(2-
methoxyethyl) 
phthalate 
117-82-8 SVHC included on the candidate list 
for authorisation 
No 
Diisobutyl 
phthalate 
84-69-5 SVHC included on the candidate list 
for authorisation 
No 
Dihexyl 
phthalate 
84-75-3 SVHC included on the candidate list 
for authorisation 
No 
Bisphenol BPA - 
Bisphenol A 
4,4'-
isopropylidene
diphenol 
80-05-7 Restriction in thermal paper 
(ECHA 2015b) 
Yes 
Per/Poly 
fluorinated 
compounds  
PFOA  
Pentadecafluor
ooctanoic acid 
335-67-1 SVHC on the candidate list for 
authorisation 
No 
PFOS 
Heptadecafluo
rooctane-1-
sulphonic acid 
1763-23-1 
APFO 
Ammonium 
pentadecafluor
ooctanoate 
3825-26-1 
PFNA 
Perfluoronona
n-1-oic acid 
375-95-1 
PFDA 
Nonadecafluor
odecanoic acid 
335-76-2 
PFDoA  
Tricosafluorod
odecanoic acid 
307-55-1 
Cadmium & 
Chromium 
Cadmium 7440-43-9 Restrictions No 
Chromium 
trioxide 
1333-82-0 SVHC requiring authorisation No 
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Substance 
group 
Substance CAS 
Number 
Evaluation under REACH RA 
scheme 
Use of 
HBM data 
Chromium VI 
compounds 
-  SVHC requiring authorisation No/ 
(yes*) 
PAHs 
(Polycyclic 
Aromatic 
Hydrocarbo
ns) 
BaP  
Benzo[a]pyren
e 
50-32-8 Restriction No 
BeP  
Benzo[e]pyren
e 
192-97-2 
BaA  
Benzo[a]anthr
acene 
56-55-3 
CHR  
Chrysen 
218-01-9 
BbFA 
Benzo[b]fluora
nthene 
205-99-2 
BjFA  
Benzo[j]fluoran
thene 
205-82-3 
BkFA  
Benzo[k]fluora
nthene 
207-08-9 
DBAhA 
Dibenzo[a,h]an
thracene 
53-70 
Anilines MOCA  
4,4'-
methylenebis[2
-chloroaniline] 
101-14-4 SVHC requiring authorisation 
(ECHA, 2015c) 
Yes 
MDA 
4,4’-
methylenediani
line 
101-77-9 SVHC requiring authorisation 
(ECHA, 2015d & 2017a) 
Yes 
Flame 
retardants 
Tris(2,3-
dibromopropyl) 
phosphate 
126-72-7 Restriction No 
DecaBDE 1163-19-5 Restriction No 
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Substance 
group 
Substance CAS 
Number 
Evaluation under REACH RA 
scheme 
Use of 
HBM data 
Bis(pentabrom
ophenyl) ether 
 
(*)  Some chromium(VI) authorization applications used occupational biomonitoring data in exposure assessment and 
in some cases biomonitoring of workers were added as an additional condition for authorization 
 Food safety 
In 2012, EFSA published a guideline for risk assessment of contaminants in food and feed (EFSA 
2012). It aimed to provide an overview of the working principles used by the EFSA Panel on 
Contaminants in the Food Chain (CONTAM Panel) and gave an outlook for future perspectives of 
risk assessments of contaminants in food and feed.  
The CONTAM Panel’s task is to assess whether or not exposure to a chemical contaminant in food 
is likely to be associated with adverse health effects in the European population, or in farm 
animals, fish and pets in Europe, or to represent a risk to the consumer of foods of animal origin. In 
contrast to EFSA Panels dealing with regulated substances, the CONTAM Panel relies on scientific 
information that is in the public domain. 
The risk assessment of chemical contaminants in food relies on the integration of two components: 
knowledge about the human exposure to these substances via food and other routes (i.e. 
occurrence data in food and food consumption data), and their potential to cause adverse health 
effects (i.e. the hazard). Whenever possible, the CONTAM Panel establishes an exposure level at 
which there is no appreciable health risk, called a health-based guidance value (HBGV) such as a 
tolerable daily intake (TDI). In the identification and characterisation of the hazard the Panel takes 
into account all toxicological information available, including studies on humans, experimental 
animals, cell- and other systems. In the absence of toxicity data from humans, the HBGV is usually 
based on data from repeated-dose studies on experimental animals, such as chronic toxicity or 
multigeneration studies in rats and mice. For the establishment of an HBGV, a reference point (RP) 
needs to be identified, based, if possible, on mathematical modelling of the dose-response 
relationship. The EFSA Scientific Committee recommended the use of a benchmark dose lower 
confidence limit (BMDL) as the RP (EFSA, 2009). The BMDL is an estimate of the lowest dose that 
is 95 % certain to cause no more than a specified change in response over background. If 
modelling is not considered appropriate, another RP may be used such as the NOAEL, which is 
the highest dose not causing a statistically significant adverse effect compared to the controls. The 
HBGV is established by dividing the RP by uncertainty factors to account for extrapolation from 
animals to humans and for variability in human sensitivity. 
For some substances the CONTAM Panel assesses if the substance could give rise to acute 
health effects in relation to short periods of intake (e.g. certain metals, opium alkaloids, some 
mycotoxins or marine biotoxins) and establishes, if possible, an acute reference dose (ARfD) as 
the HBGV for such substances (EFSA, 2012).This is usually based on short-term toxicity data from 
experimental animals (e.g. acute toxicity or developmental toxicity), but also based on human data 
when available (e.g. pharmacological activity of opium alkaloids, outbreaks of food poisoning 
caused by some marine biotoxins). 
For substances that cause genotoxicity by a mechanism involving reaction with DNA, it is not 
possible to identify a dose threshold of effect. Until 2005, the advice given by the risk assessor to 
the risk manager was to reduce exposure to such substances to a level that is as low as 
reasonably achievable (known as the ALARA principle). However, it was long recognised that such 
advice does not provide risk managers with a basis for setting priorities for action, either with 
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regard to the urgency or to the extent of measures that may be necessary. To overcome this, the 
EFSA Scientific Committee proposed the margin of exposure approach as a harmonised approach 
for the risk assessment of substances that are both genotoxic and carcinogenic. 
Human biomonitoring in the assessment of food contaminants  
In some cases, the CONTAM Panel has been able to model human data and to incorporate 
information from biomarkers of exposure or of effect in the characterisation of the hazard, e.g. 
cadmium and lead (EFSA, 2009; EFSA Panel on Contaminants in the Food Chain (CONTAM), 
2010). This allows the use of a body burden approach, where an estimate of systemic exposure 
(body burden), rather than external dose, is used in the risk characterisation. HBM data are, 
however, currently not used for refinement of exposure assessment on a regular basis. Usually 
food monitoring data are used for refinement, when applicable. 
On the other hand, EFSA has recently published overviews on the use of HBM in the risk 
assessment of food contaminants. That is the case of two recent papers, namely: “Review of the 
state of the art of human biomonitoring for chemical substances and its application to human 
exposure assessment for food safety” (Choi et al., 2015) and “Identification of exposure to 
environmental chemicals in children and older adults using human biomonitoring data sorted by 
age: Results from a literature review” (Choi et al., 2017).  
The first document is an EFSA External Scientific Report that is based on a literature search 
performed in several databases and conference proceedings for 2002 – 2014. It comprises the 
following information: 
 Definitions of HBM and biomarkers, HBM techniques and requirements, and the possible 
application to the different steps of risk assessment.  
 Evaluation of the usefulness of HBM for exposure assessment of chemical substances from 
food source, and for the implementation of a systematic Post Market Monitoring approach 
for regulated chemical substances. 
An inventory of HBM programmes (38) with detailed information about study design, analytical 
methods, and reference values (RVs) and biomarkers used is also made. Substances covered 
include metals, PCBs; cotinine; mycotoxins; perchlorate; nitrosamine; alkaloids; dioxins; 
phthalates; PAHs; furans; fluorocarbons; organochlorines; phenols; Perfluorinated compounds 
(PFCs); Polybrominated Diphenyl Ethers (PBDEs); organophosphates; pyrethroids; chlorinated 
phenols; acrylamide; carbamates. Environmental monitoring and associations between HBM 
values and food, as well as coverage of substances and remaining deficits are highlighted. The 
review of study results provides also information on emerging chemicals, higher exposed and 
particularly vulnerable populations. 
In addition, in the second paper above referred, EFSA has conducted a separate literature study 
on the identification of exposure to environmental chemicals in children and older adults using 
human biomonitoring data sorted by age (Choi et al 2017). This is a review aimed at demonstrating 
the use of HBM to identify environmental chemicals that might be of concern for two vulnerable 
populations: children or older adults. Children are considered vulnerable populations when it 
comes to exposure of environmental chemicals for a number of reasons such as the children’s 
continuing development and behavioural activities, smaller body storage for compounds due to 
their smaller body size and blood volume capacity as well as less mature metabolic pathways, 
which might lead to longer half-lives in the body. Older adults and the elderly are particularly 
vulnerable to chemical exposure for a number of other reasons, such as physiological and cellular 
damages that may have accumulated over time, and metabolic processes that might have slowed 
down or be pathologically altered due to disease. The effect of aging on the decreased function of 
organ systems responsible for elimination of xenobiotics might result in longer half-lives of 
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environmental chemicals in the body, consequently allowing more time for these chemicals to elicit 
their deleterious effects on a physiologically-weakened older population. 
Human biomonitoring has been presented by Choi et al. (2017) as a unique approach of 
monitoring the internal exposure to chemicals in these vulnerable populations. Since the objective 
of this review was to provide an overview of environmental chemicals identified from existing 
national HBM surveys/programs to be of concern for children or older adults and to further 
elaborate on the findings regarding these identified chemicals, national HBM programs from an 
EFSA survey were selected based on the following criteria: i) Cross-sectional HBM of the general 
population that is representative of the country; ii) Sample size of ≥ ∼1000 subjects; iii) Analysis of 
environmental chemicals in biological matrices. 
 A total of 10 national HBM programs under these criteria were identified (Choi et al., 2017): 
GerES; CZ-HBM; NHANES; FLEHS; KorSEP; ENNS; BIOAMBIENT.ES; Slovenia’s HBM; CHMS 
and PROBE. DEMOCOPHES’ results are described in the text, but are not included in the tables, 
since it does not meet the above criteria. 
Choi et al. (2015) gives some guidance how HBM can be used for RA. It is stated that, although 
HBM alone is not able to provide information about health risk from chemical exposure, it can be 
used in combination with other tools to serve this purpose. In the author’s view, for interpretation in 
risk assessment, HBM data should be combined with other data and tools such as environmental 
and health registry data, modelling data from physiologically-based pharmacokinetic (PBTK/PBPK) 
models, or HBM-based guidance values such as Human Biomonitoring Values (HBM-I and HBM-II, 
Schulz et al., 2011; Apel et al., 2017) and Biomonitoring Equivalents (BE, Hays and Aylward, 2009) 
that translate established health-based guidance values (e.g., ADIs/TDIs and reference doses) or a 
POD from an animal toxicity study (BMDL or NOAEL) into a biomarker concentration. To this point, 
EFSA states that HBM can be used to raise awareness (Choi et al., 2015). 
The example of the concern that was raised by DEHP metabolite levels of the children exceeding 
the HBM-I value in the GerES IV study or of the Cd exposure in China is described in this 
document, showing that these data indicated increased risk of adverse health effects and that 
intervention measures to reduce the body burden are urgently needed. Furthermore, it is 
exemplified how HBM data, along with personal information collected from participants or 
environmental monitoring, can provide important clues to identify potential sources of exposure 
and can explain exposure trends, which might help to explain the different findings observed in 
different countries or regions, especially concerning food consumption patterns. 
EFSA concludes that large-scale cross-sectional national HBM programs can provide useful data 
and information on chemical exposure of the general population. The study designs of these large-
scale programs should be well-planned, tested with pilot studies, adjusted, and appraised over 
time such that findings from these programs can serve as a useful and reliable basis for further 
investigation, e.g., allowing comparative analyses of chemical concentrations and/or exposure 
trends among different countries (Choi et al., 2015). 
An advantage of HBM (especially large-scale national HBM programs) would be the assessment of 
internal dose in humans upon chemical exposure, and with recruitment of participants of all ages, 
HBM data can be stratified by age to identify chemicals that show higher body burden in children or 
older adults. Therefore, Choi et al. (2015) consider HBM as a powerful tool for exposure 
assessment of chemicals in humans. In addition, guidelines for a proper HBM study design are 
enunciated. HBM should include: 
 recruitment of participants of all ages 
 collection of sufficient data from participants 
 conducting data analysis that can be stratified by various factors 
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In this way, HBM outcomes might provide useful and reliable information for identifying vulnerable 
populations such as children and older adults and the environmental chemicals that might be of 
concern for them (Choi et al., 2017). Such identification can facilitate policy makers to focus their 
efforts to ensure that the chemical exposure in vulnerable populations can be reduced as much as 
possible, thereby reducing their body burden and potential risks of adverse health effects. 
By conducting analysis using age-stratified data from national HBM programs and studies can 
bring added value of identifying chemicals of potential concerns in children and older adults in 
general. This review focuses primarily on age to identify these two particular vulnerable 
populations and the chemicals of concern for these populations, but other factors such as gender, 
socioeconomic status, education, and lifestyle habits (e.g., smoking and alcohol consumption) can 
also be considered when stratifying and analysing HBM data in order to identify other vulnerable 
populations regarding chemical exposure. 
In addition, the paper has reference to HBM4EU: Harmonisation efforts performed in 
DEMOCOPHES will continue as 26 countries and the European Commission will collaborate and 
work together in the European Joint HBM Initiative called HBM4EU with potential options of 
studying age-related exposures of environmental chemicals.  
Considering the ageing world population, HBM is described as useful for the authorities by 
monitoring chemicals that might be of concerns (e.g., metals and some persistent pollutants) for 
older adults as well as providing additional information on concentrations of other environmental 
contaminants including emerging chemicals. An example where HBM data could help policy is the 
Third EU Health Program (“Health for Growth”) from 2014 to 2020, which one of the objectives is 
“fostering good health in an ageing Europe” (European Commission, 2016). There is currently a 
paucity of programs that specifically aim to investigate body burden in older adults, but recruitment 
of participants in national HBM programs often include older adults. Evaluation of chemical 
exposure in older adults can then be conducted using age-stratified data from the national HBM 
programs. 
HBM4EU priority substances evaluated by Food safety RA schemes 
Over the nine years since its inception, the CONTAM Panel has assessed human and animal 
health risks related to the presence of persistent organic pollutants, natural toxins and plant 
toxicants, metals and metalloids, reaction products from thermal food processing, cross-
contamination of feed for non-target animals with chemicals authorised for use such as feed 
additives, or non-authorised substances such as hormones, and complex mixtures such as mineral 
hydrocarbons in food and/or feed.  
The CONTAM Panel conducts risk assessments on an enormous range of different types of 
chemicals, adapting its approach depending on the types of data that are available, and the 
specific question that has been asked. It is anticipated that future work will include instances where 
previously uninvestigated environmental contaminants have been detected in food or feed.  
Concerning the papers described above (Choi et al., 20015, 2017), in the overviews on the use of 
HBM in the risk assessment of food contaminants, the following substances were mentioned: 
Metals; PCBs; cotinine; mycotoxins; perchlorate; nitrosamine; alkaloids; dioxins; phthalates; PAHs; 
furans; fluorocarbons; organochlorines; phenols; PFCs; PBDEs; organophosphates; pyrethroids; 
chlorinated phenols; acrylamide; carbamates. In addition, twelve classes of chemicals were 
identified to have higher body burden in either children or older adults. There is consistent 
evidence from multiple national HBM programs to show higher body burdens of BPA and some 
PAH metabolites in children and of heavy metals and persistent chemicals such as organochlorine 
pesticides in older adults. The 12 classes of environmental chemicals that were shown to have 
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higher body burden in children or older adults when compared to other age groups have been 
listed in (Table 5). 
Table 5: Chemicals showing higher body burdens in children or elderly (Choi et al., 2017) 
Chemicals showing higher body burden in 
children 
Chemicals showing higher body burden in 
older adults or elderly 
PCBs (PCB 28) PBDEs (PBB 153) 
PBDEs (BDE 28, BDE 47, BDE 99, BDE 100, 
BDE 153) 
Metals (arsenic, cadmium, lead, mercury, 
palladium, selenium) 
PFAS (PFOA) PFAS (PFOS) 
PAHs (1-hydroxypyrene, 3-
hydroxyphenanthrene) 
Organochlorine pesticides (DDE, p,p’-DDE, 
Hexachlorobenzene, β-
Hexachlorocyclohexane, Mirex, cis-Nonachlor, 
trans-Nonachlor, Oxychlordane, Toxaphene 
parlar 50) 
Parabens (Methyl paraben, propyl paraben) 
Perchlorate 
Bisphenol A 
Phytoestrogen (Daidzein, Genistein, O-
Desmethylangolensin) 
Parabens (Methyl paraben, Propyl paraben) 
Volatile organic compounds (VOCs) (t,t-MA)  
 EU plant protective products legislation 
Plant protection products (PPPs) are pesticides used to keep crops healthy and prevent them from 
being destroyed by disease and infestation. They include herbicides, fungicides, insecticides, 
acaricides, plant growth regulators and repellents. PPPs contain at least one active substance (the 
active component against pests/plant diseases). Before an active substance can be used within a 
plant protection product in the EU, it must be approved by the European Commission. Member 
States evaluate and authorise the products at national level. 
The process for deciding whether a new active substance can be approved for use in PPPs, in the 
EU, involves all Member States, the European Food Safety Authority (EFSA) and the European 
Commission. Members of the public and other interested parties can also provide comments for 
consideration in the process, specifically through the public consultation process of EFSA. Each 
active substance has to be proven safe in terms of human health, animal health and impact on the 
environment. 
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EU legislation 
PPPs are mainly regulated by framework Regulation (EC) No 1107/2009. Data requirements are 
given in Commission Regulation (EU) No 283/2013 (for the active substance) and Commission 
Regulation (EU) No 284/2013 (for the PPP). 
All matters related to legal limits for pesticide residues in food and feed are covered by Regulation 
(EC) No 396/2005. This regulation also contains provisions on official controls of pesticides 
residues in food of plant and animal origin that may arise from their use in plant protection. 
Pesticide evaluations: overview and procedure 
Active substances undergo an exhaustive evaluation process before a decision can be made on 
approval. To support an application for an active substance a complete 'dossier' must be submitted 
which must fully address the data requirements. The risk assessment of active substances 
evaluates whether, when used correctly, these substances are likely to have any direct or indirect 
harmful effects on human or animal health – for example, throughout the food chain and 
occupational exposure. In addition, the environmental risk assessment aims to evaluate fate and 
behaviour in the environment including the potential impact on non-target organisms. 
Active substances 
For the review of each active substance, applicants have to submit an application dossier, 
containing scientific information and studies, through a national contact point. A Member State is 
appointed as a “rapporteur” (RMS) to carry out an initial risk assessment and to prepare a Draft 
Assessment Report (DAR) which EFSA peer reviews.5 
A similar process also operates for the renewal of active substances already approved for use in 
PPPs (Regulation (EU) No 844/2012).  
The dossier should accomplished format requirements agreed by the OECD for regulatory dossier 
structure. The complete dossier is a very extensive set of documentation comprising not only the 
required tests and studies, but also a series of supporting documents providing background 
information on the active substance and its uses. A set of 'tiered' summaries detailing the 
applicant's evaluation and risk assessment for the active substance and product (the summary 
dossier) is required in addition to the complete copies of all the individual study reports. 
To enable a risk assessment to be conducted, at least one PPP application must be supported by 
the dossier with comprehensive data required for approval of the active substance. 
The dossier is evaluated by experts in the areas of: identity, physical chemical properties; 
analytical methods; mammalian toxicology; operator exposure; residues; efficacy; environmental 
fate and behaviour and ecotoxicology. 
Mammalian toxicology of active substance is assessed on the basis of the standard toxicological 
data on acute and repeated/long-term toxicity as well as irritation, sensitising, mutagenic and 
reproductive effects. In addition, medical data (medical surveillance on manufacturing plant 
personnel and monitoring studies, diagnosis of poisoning) and other data collected on humans 
(direct observations, epidemiological studies) are taken into account. 
Mammalian toxicology of PPP is assessed on the basis of following studies acute toxicity data on 
the product (oral toxicity, dermal toxicity, inhalation toxicity, skin irritation, eye irritation and skin 
                                               
5 http://www.efsa.europa.eu/sites/default/files/applications/apdeskapplworkflowpesticidesnasub.pdf 
http://www.efsa.europa.eu/sites/default/files/applications/NewActSubstancesProcedure.pdf 
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sensitisation) supplementary studies on the PPP and supplementary studies for combinations of 
PPPs.  
Operator exposure (occupational exposure) to PPP is assessed on the basis of modelled or 
measured operator exposure data and data on dermal absorption. Available toxicological data 
relating to co-formulants is also taken into account in the assessment. 
The approval of plant protective products involves the comparison of estimated human exposure 
with RVs below which it is considered there are no expected adverse health effects. As we just 
described, pesticide producers must provide extensive animal (and environmental) toxicity test 
data to be used to assess the risk to occupational population (operator, worker) and general 
population (bystander, resident and consumer) under different use patterns. If a risk to operator, 
bystander, resident or worker is identified, risk management measures to reduce exposure should 
be assessed, e.g. use of personal protection equipment, mitigation measures and labelling. 
Following detailed evaluation of the dossier, the RMS produces a report of their evaluation “the 
Draft Assessment Report (DAR)”, which is peer reviewed by the other Member States and EFSA to 
reach consensus, based on which EFSA makes its conclusions.  
The EFSA conclusion is a key document as it presents a comprehensive independent summary of 
the risk assessment process. It summarises the specific conclusions, RVs and endpoints; identifies 
particular conditions that may need to be considered in relation to the risk; and the critical areas of 
concern. The final conclusion is sent to the European Commission. 
Human biomonitoring in pesticide evaluation 
There’s no a specific guideline that describes the use of HBM data. However, human biomonitoring 
as a tool for occupational exposure assessment related to the use of PPPs has been reviewed in a 
recent paper (EFSA 2017: EN-1185. 207 pp.). 
The main objectives of the report were as follows: 
1. To provide an overview on the use of HBM as a tool for occupational exposure assessment 
refinement, identifying advantages, disadvantages and needs for further development.  
2. To provide a review of available HBM studies/surveillance programmes conducted in 
EU/US occupational settings to identify pesticides (or metabolites) both persistent and not 
persistent, for which biomarkers of exposure (and possibly effect) are available and 
validated.  
A systematic review with defined inclusion and exclusion criteria according to EFSA methodology 
(EFSA 2010) of the literature databases Scopus, Web of Science and PubMed was performed for 
the period 1990 to 2015 (December). The search identified 2096 publications relating to the use of 
HBM to assess occupational exposure to pesticides (or metabolites). Additional information was 
collated from individual searches to identify grey literature and reports, international evaluations or 
monographs and conference proceedings of appropriate societies/organisations and any 
associated journals. 
HBM is being used more frequently as part of an occupational health and safety strategy, as a tool 
for refined exposure assessment and in order to contribute to the evaluation of potential health 
risks from occupational exposure to pesticides. HBM essentially involves the quantification of either 
a substance, its metabolites, or a surrogate marker of its effects in a biological sample obtained 
from a person who may have been exposed. Thus, HBM is considered to be an estimate of 
exposure, rather than a measure of health, and should be employed alongside environmental 
monitoring as a tool to characterise exposure. 
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Under the previously described regulation for PPP, human data in the form of epidemiology 
studies, toxicokinetic and metabolism studies, or tests on skin irritation or skin sensitisation, are 
required to be submitted if available. However, RVs are established based on animal studies. The 
exception to this is where “appropriate scientifically valid and ethically generated human data are 
available and show that humans are more sensitive and lead to lower regulatory limit values”. This 
apparent contradictions within Regulation (EC) No 1107/2009 appear to deter manufacturers from 
producing, and therefore reporting, such data. There is also a requirement under 283/2013 that 
“Methods shall be submitted, with a full description, for the determination of non-isotope-labelled 
residues in all areas of the dossier, as set out in detail in the following points: in body fluids, air and 
any additional matrices used in support of operator, worker, resident and bystander exposure 
studies”, however it is not clear whether this requires data to be generated or just that methods are 
to be reported if data has been generated. 
There are no established methods to estimate human exposure and therefore applicants may use 
measurements made during application or other steps in the process with the PPP, other 
analogous measurement data, or one of a number of data base or exposure models (e.g.UK-
POEM, BBA model, EUROPOEM II, AOEM, SeedTropex, PHED, Southern Greenhouse model, 
ConsExpo, BREAM). A range of exposures are typically estimated, including for pesticide 
applicators, post application workers, and bystanders or neighbours and consumers. In reality, very 
few exposure measurements are submitted as part of the approvals process (and these are usually 
exclusively environmental data not HBM); the vast majority of the exposure assessments rely on 
modelled data. 
The use of HBM-data for operator or bystander exposure assessment requires appropriate 
characterisation of background exposure. 
An OECD Guidance Document for the Conduct of Studies of Occupational Exposure to Pesticides 
During Agricultural Application (OECD /GD(97)148) has also looked to provide some harmonised 
guidance on exposure studies in this area. In this document, human biomonitoring is 
recommended as a potential “Tier 3” approach, for cases where generic exposure data plus 
information on dermal absorption and protective measures result in either insufficient data or 
unacceptable risk. 
HBM has been extensively used for monitoring worker exposure to a variety of pesticides. A 
commonly reported problem when carrying out epidemiology studies is the difficulty in 
characterising exposure. Occupational exposure to pesticides may vary in relation to crop, climate, 
microclimate, task, application method, personal protection equipment, clothing, and personal 
hygiene. Epidemiological studies on occupational pesticide use (e.g. agricultural pesticide 
applicators, agricultural workers) are often limited by inadequate or retrospective exposure 
information, are typically obtained through self-reported questionnaires, which can potentially lead 
to erroneous exposure results. There are very limited data studying seasonal exposures. 
Exposure assessment is a key part of all epidemiological studies and misclassification of exposure 
and use of simple categorical methods are known to weaken the ability of a study to determine 
whether an association between contact and ill-health outcome exists. At present, this limits 
integration of epidemiological findings into regulatory risk assessment.  
The validity of regulatory exposure assessments (i.e. generated through use of models) has been 
investigated through comparison with exposures estimated from non-occupational biomarker 
studies (Cochran, 2002; Krieger et al., 2012; CDC, 2009). Findings suggested the models to be 
conservative, i.e. not realistic, in their estimates of exposure. 
It is apparent that HBM has a role to play in the validation of exposure assessments models as well 
as in measuring actual exposures for the approvals process. As noted above, when checked, the 
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models have often been found to be over conservative – this may lead to inappropriate or overly 
proscribed control measures, which in themselves can increase exposure (e.g. sweating due to 
overly cumbersome personal protection equipment may increase skin absorption; reused gloves 
will increase contamination). If exposure assessment models are comprehensively validated 
against HBM studies then adjustments can be made to the parameter assumptions within the 
models, leading to more realistic evaluations of exposure. Such validation studies would also allow 
identification of the critical exposure parameters (e.g. application device or volatility of active etc.). 
One important tool used for risk assessment of pesticide workers in the EU is the Acceptable 
Operator Exposure Level (AOEL). This is a health-based limit value against which non-dietary 
exposures to pesticides are currently assessed. It is intended to define a level of daily exposure (in 
milligrams/kilogram body weight/day) throughout a spraying season, year on year, below which no 
adverse systemic health effects would be expected. The AOEL is normally derived by applying an 
assessment factor (often 100, 10X Animal to Human Extrapolation and 10X Human Variability or 
Individual Sensitivity) to a NOAEL (corrected if appropriate for incomplete absorption) from a 
toxicological study in which animals were dosed daily for 90 days or longer. Less often, the critical 
NOAEL comes from a study with a shorter dosing period (e.g. a developmental study). 
The concept of the AOEL as such has relevant legislative consequences, as exposure estimates 
exceeding the AOEL do not, for example, allow an inclusion of active substances in Annex I of 
Directive 91/414/EC. Draft guidance for the setting of AOELs was published by European 
Commission in 2005, and although there is a current formal harmonised approach for the 
derivation of AOEL in Europe, this is subject to ongoing review. The benchmark dose (BMD) 
approach, as an alternative to the traditionally used NOAEL, involves analysing dose-response 
data from experimental studies, and to look at the possible application of this approach to data 
from observational epidemiological studies.  
There are very few health-based HBM values or biological equivalents (BEs) for occupational 
exposure to currently used pesticides which limits the use of human biomonitoring. A further 
consideration for HBM is the inability to differentiate exposure from sources other than the one(s) 
under investigation. Because HBM integrates exposure from all sources, in the occupational field, 
potential contribution from environmental or dietary sources should also be considered. Following 
application, pesticides may undergo breakdown in the environment due to both chemical and 
microbial action. This may result in the presence of hydrolysis products on and/or in food, which 
are available for dietary absorption. For example dialkylphosphates, which are frequently 
measured in urine to reflect exposure to organophosphates, have been reported at relatively high 
levels on a variety of fruit and vegetables, which have the potential to result in a significant 
overestimation of organophosphate exposure. Thus, it is not always comprehensible if biomarkers 
(often metabolites) found in urine are part of human or plant metabolism and whether consumers 
were exposed at all to the unchanged active substance. Consequently, these potential effects 
should be predictable and, therefore, suitable investigations should be carried out to assess any 
confounding effects on HBM results.  
On the other hand, there is limited information on the exposure of residents living near agricultural 
land. Pesticide HBM studies could provide relevant information in this area of concern. 
Post-approval occupational health surveillance for pesticides in the EU 
There is currently no requirement in the EU for post-approval monitoring of exposure to pesticides, 
through either occupational and/or environmental routes. However, long-term health effect studies 
have been set up to look at the relationships between pesticide exposure and possible adverse 
health effects within agricultural cohorts, the data from which can be used to inform regulatory 
policies and practice. There are many examples of such studies in Europe and USA, and these 
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have been brought together in a consortium, AGRICOH, which was set up in 2010 by the US 
National Cancer Institute and is coordinated by the International Agency for Research on Cancer 
(IARC). The consortium was set up to encourage and support data pooling to study disease 
exposure associations that individual cohorts would not have sufficient statistical power to study.  
Although there are many studies which can be called “post-approval assessment studies”, which 
look at occupational exposure to pesticides using HBM (as the active substance has been 
approved), in reality there are very few studies that compare actual exposure against assumed 
exposure during the approvals process. 
Conclusions and future research needs and recommendations given by EFSA (2017) 
In the regulatory framework for pesticide active substance approval, the vast majority of the 
exposure assessments rely on modelled data. In reality, very few exposure measurements are 
submitted as part of the approvals process (and these are usually exclusively environmental data 
not HBM).  
It was proposed that the collection of human biomonitoring data for pesticide workers could be 
added as a routine component of existing occupational health surveillance programmes; for 
example, the European Human Biomonitoring Initiative could be a vehicle for gathering such data.  
The authors used identified evidence to formulate recommendations on the implementation of 
HBM as part of the occupational health surveillance for pesticides in Europe, examples as follows: 
 Priorities for the development of new biomarkers for all pesticides considering toxicological 
concern; conduction of cohort studies with focus on young farmers 
 Derivation and adoption of health-based guidance values, as only few HBM values for 
occupational exposure of currently used pesticides are available 
 Guarantee of the quality and comparability of occupational HBM data across the EU 
including developing and publishing of quality assurance schemes to validate inter-
laboratory measurements and encourage confidence in data sharing.  
 Design of Standard Operating Procedures (SOPs) for field work  
 Design of questionnaires to support exposure assessment  
 Implementation of strategies for establishing and co-ordinating biobanking  
 HBM data and policy guidance and/or evaluation implying that HBM has a role to play in the 
validation of exposure assessment models allowing adjustments to be made to reflect more 
realistic evaluations and allow identification of critical exposure parameters. There is 
currently no requirement in the EU for post-approval monitoring of exposure to pesticides, 
through both occupational and environmental routes. 
Although the use of volunteer studies is not permitted within the framework of Reg. (EC) No. 
1107/2009 and Reg. (EU) No. 528/2009, information obtained from post-marketing epidemiological 
studies may be taken into account for the risk assessment for active substance re-approval. New 
guidance is to be expected from EFSA on the use of epidemiological data in pesticide risk 
assessment in the near future (currently under review). 
HBM4EU priority substances evaluated under PPP legislation  
Prioritised substances have not been evaluated under this scheme, but attention should be drawn 
to the risk assessment of mixtures of pesticides. The recently started H2020 EuroMix project will 
deliver a mixture test strategy and test instruments using novel techniques. In addition, the EFSA’s 
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scientific report (EFSA Journal 2013;11(7):3313) reviews the terminology, methodologies and 
frameworks developed by national and international agencies for the human risk assessment of 
combined exposure to multiple chemicals and provides recommendations for future activities at 
EFSA in this area. 
 Biocides 
For the biocides risk assessment scheme, the following guidance has been published: “Guidance 
on the Biocidal Products Regulation - Volume III, Part B - Human Health Risk Assessment” (ECHA, 
2013). 
The risk assessment process for the biocides active substances follows the same principles of the 
EU risk assessment schemes which means, in case of human health, a sequence of actions 
starting with the (1) Assessment of effects (hazard identification: identification of the adverse 
effects which a substance has an inherent capacity to cause; and hazard characterisation: dose 
(concentration) - response (effects) assessment: estimation of the relationship between dose, or 
level of exposure to a substance, and the incidence and severity of an effect, where appropriate) 
(2) Exposure assessment: estimation of the concentrations/doses to which human populations (i.e. 
workers, consumers and man exposed indirectly via the environment) are or may be exposed.(3) 
Risk characterisation: estimation of the incidence and severity of the adverse effects likely to occur 
in a human population due to actual or predicted exposure to a substance, and may include “risk 
estimation”, i.e. the quantification of that likelihood. Combined exposure to multiple chemicals and 
dietary risk assessment are also considered where relevant. 
Human Biomonitoring in biocides evaluation 
HBM is not part of active substance approval within the framework of Reg (EC) No. 1109/2006 and 
Reg (EU) No. 528/2012 under a regular basis however existing human data may be used in some 
cases to derive RVs for risk assessment. The Human Health risk assessment scheme for the 
biocidal active substances doesn’t include a specific guidance on the use of HBM though several 
considerations to biological biomonitoring are made in the Guidance for Human Health Risk 
Assessment, Volume III, Part B.  
It is to be noted that the Biocidal Human Health risk assessment is performed making use of a data 
package submitted by the applicants and evaluated by Member State Competent Authorities, in 
order to evaluate safe uses. These data can be generated by in vitro and/or in vivo experimental 
studies, justified waivers and read-across arguments, addressing an extensive list of toxicological 
endpoints.  
Human biomonitoring data are not part of the core information requirements under the BPR but, 
when available, may be used to refine the assessment and support several decisions. It is accepted 
that the use of scientifically valid human data may reduce the level of uncertainty in comparison to 
extrapolation from animal models and is seen as a valuable contribution to science-based decision 
making. Biomonitoring studies, epidemiological data and medical poisoning records can be some of 
the sources of human data.  
Human volunteer studies should not be performed for the purposes of the BPR however can be 
requested for products already authorised for use under the BPR. As a prerequisite for the 
consideration of the use of human volunteer studies that have been performed, clear statements that 
they were performed in accordance with internationally accepted ethical standards should be 
provided (Charnley et al, 2004), e.g. the Declaration of Helsinki (World Medical Association, 1997). 
In some cases, the use of human data in regulatory safety assessment might lead to more stringent 
exposure limits for some biocides than those that would have been derived on the basis of animal 
data only. It should be noted that modification of the dose descriptor is not appropriate in cases 
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where human exposure is evaluated based on human biomonitoring data. In such cases (availability 
of valid HBM data), the calculation of Acceptable Exposure Level (AEL)/ Acceptable Exposure 
Concentration values can be used straightforward if studies in animals or humans are available 
which relate the effect directly or indirectly to the biomonitoring metric. 
There are specific endpoints in the biocides risk assessment where the inclusion of human 
biomonitoring studies are considered very useful, for instance, to refine the toxicokinetic assessment, 
namely, to provide dosimetric means for establishing aggregate and/or cumulative absorbed doses 
of chemicals following specific situations or exposure scenarios or for establishing baseline, 
population-based background levels (Woollen, 1993). Temporal situational human biomonitoring can 
provide a realistic description of human exposure. The routine analysis of human tissues or excreta 
for direct or indirect evidence of human exposures to substances, can provide unique insights into 
the relationship between dose and putative toxicity thresholds established in experimental animals, 
usually rats. On the other hand, HBM information is seen as equivalent (i.e. as having neither greater 
nor lesser importance) to other forms of exposure data and these results reflect an individual’s total 
exposure (oral, dermal and inhalation) to a substance from any source, i.e. from consumer products, 
and/or from the environment and not just for a specific type of exposure (occupational exposure). 
Data from controlled human exposure studies are even more unlikely available due to the practical 
and ethical considerations involved in deliberate exposure of individuals. It is referred that the most 
appropriate way of assessing total systemic exposure is by human biomonitoring, however, the 
interpretation requires detailed pharmacokinetic information on the compound involved. In 
conclusion, HBM is considered as Tier 3 level of risk assessment. 
In Carcinogenicity (chapter 7), Guidance for Human Health Risk Assessment, Volume III, Part B, it 
is referred that techniques for biomonitoring and molecular epidemiology promise to provide 
information on biomarkers of individual susceptibility, critical target organ exposures and whether 
effects occur at low exposure levels. Such ancillary information may assist in the interpretation of 
epidemiology study outcomes and the definition of dose response relationships. For example, 
monitoring the formation of chemical adducts in haemoglobin molecules (Albertini et al., 2006), the 
urinary excretion of damaged DNA bases (Chen, H.J. and Chiu, W.L. (2005), and the induction of 
genotoxicity biomarkers (micronuclei or chromosome aberrations; Boffetta et al., 2007) are presently 
being evaluated and/or validated for use in conjunction with classical epidemiological study designs. 
Such data are usually restricted in their application to specific chemical substances but such 
techniques may ultimately become more widely used, particularly when combined with animal data 
that defines potential mechanisms of action and associated biomarkers that may be indicative of 
carcinogenic risk. Monitoring of the molecular events that underly the carcinogenic process may also 
facilitate the refinement of dose response relationships and may ultimately serve as early indicators 
of potential cancer risk. However, as a generalisation, such biomonitoring tools have yet to 
demonstrate the sensitivity requisite for routine use. 
In ‘Human data on reproductive toxicity’ (chapter 8.2.3), it is mentioned that epidemiological studies, 
conducted in the general population or in occupational cohorts, may provide information on possible 
associations between exposure to a chemical and adverse effects on reproduction. Clinical data and 
case reports (e.g. biomonitoring after accidental substance release) may also be available. 
HBM4EU priority substances evaluated under biocides regulation 
HBM data are only exceptionally used for the risk assessment of biocidal active substances. This 
was the case, for instance, of iodine where an upper intake level set from human studies was used 
to derive the AEL values for the different time frames and the ADI. 
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It is noticed that there are no biocidal active substances within the current HBM4EU priority 
substances groups. However, they can be included in studies with mixtures and can be part of 
emerging chemicals studies.  
 Occupational risk assessment 
Legislation 
According to the EU Occupational Safety and Health (OSH) legislation (directive 89/391/EEC) it is 
the responsibility of the employer to evaluate the risks to the safety and health of workers. This 
includes also risks arising from chemical substances or preparations used. 
The Chemical Agents Directive 98/24/EC (CAD directive on the protection of the health and safety 
of workers from the risks related to chemical agents at work) lays down minimum requirements for 
the protection of workers from risks arising from the effects of chemical agents that are present at 
the workplace or as a result of any work activity involving chemical agents. 
The Directive provides the basis for the drawing up of indicative and binding occupational exposure 
limit values for workplace air (IOELVs and BOELVs, respectively) as well as biological limit values 
(BLVs) at European Community level. For any chemical for which an indicative occupational 
exposure limit value is established, Member States must establish a national occupational 
exposure limit value taking into account the Community limit value. For any chemical agent for 
which a binding occupational exposure is established at Community level, Member States must 
establish a national binding occupational exposure that is equivalent to or lower than the 
Community limit value. 
In addition to BOELVs for air concentrations, according to Chemical Agents Directive (CAD) 
binding BLV may be drawn up on the basis of the scientific evaluation of the health effects and of 
the availability of measurement techniques. Similarly to BOELVs binding BLVs take into account 
feasibility factors (technical and economic feasibility). For any chemical agent for which a binding 
BLV is established, Member States shall establish a corresponding national binding BLV based on, 
but not exceeding, the Community limit value. Where a binding BLV has been set, health 
surveillance is a compulsory requirement for work with the hazardous chemical agent in question. 
Workers shall be informed on this requirement before being assigned to the task involving risk of 
exposure to the hazardous chemical agent indicated. There is no provision for indicative BLVs in 
the Chemical Agents Directive. The only binding BLV drawn up is the limit value for blood lead (B-
Pb), which is 70 μg Pb/100 ml blood (Council directive 98/24/EC of 7 April 1998). This has not 
been updated since then although there is scientific evidence of adverse health effects at lower B-
Pb levels and the EU Scientific Committee on Occupational Exposure Limits (SCOEL) already 
recommended a biological limit value of 30 μg Pb/100 ml blood in 2002 (SCOEL, 2002). 
In addition to CAD, exposure to carcinogens and mutagens at work is regulated under Directive 
2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or 
mutagens at work (CMD directive). According to CMD the employer shall assess and manage the 
risk of exposure to carcinogens or mutagens. In addition, workers' exposure to carcinogens and 
mutagens must be prevented whenever possible. If replacement is not possible, the employer shall 
use a closed technological system. Where this is not technically possible, the employer shall 
reduce exposure to minimum. CMD Annex III lists the binding limit values for the carcinogens and 
mutagens. There are no BLVs given under CMD at this moment. However, it is stated under annex 
II of the CMD concerning health surveillance that health surveillance of the workers exposed to 
carcinogens and mutagens must include, where appropriate, biological surveillance, as well as 
detection of early and reversible effects. The Advisory Committee on Safety and Health at Work 
(ACSH) has recently released an opinion on a possible amendment of Directive 2004/37/EC on the 
D 5.1 - Human biomonitoring in risk assessment  Security: Public 
WP 5 - Translation of results into policy Version: 2.0 
Authors: Tiina Santonen Page: 35 
 
protection of workers from the risks related to exposure to carcinogens or mutagens at work to 
incorporate provisions regarding biomonitoring (EC, 2017). All interest groups of the ACSH support 
the use of biological monitoring in workers' health and safety protection provided biological 
indicators are scientifically valid and bring added value to worker protection and prevention of 
occupational ill-health. However, at present ACSH does not support the amendment of Annex II to 
directive 2004/37/EC (CMD) by including biomonitoring or biological limit or guidance values 
recommended by SCOEL. Instead, they recommend to develop EU level guidance on biological 
monitoring for both carcinogens and mutagens as well as other hazardous substances falling 
under CAD (98/24/EC). According to ACSH such guidance should indicate the significance of 
biological values and the manner in which these values could be used as part of an overall 
approach to chemical risk management at the workplace. It is also emphasised that it should be 
built on the experience in the Member States and guidance documents already developed at 
national level. Even though ACSH does not support the amendment of CMD to include the 
possibility to set binding limit values in Annex III of CMD, they have proposed to add a new point to 
Annex II of CMD which states that when biological surveillance is carried out, those undertaking 
such surveillance should take into consideration biological values recommended by SCOEL as well 
as other available guidance and information at national and EU level (European Commission, 
2017).  
SCOEL recommendations 
SCOEL has prepared several recommendations on BLVs or biological guidance values (BGVs, 
see the definition below). SCOEL recommends BLVs or BGVs case-by-case basis whenever 
human biomonitoring is considered to be an appropriate way to assess the exposure and health 
risk due to the substance, and that there are analytical methods and enough data to set a value. 
SCOEL key (guidance) documentation includes a detailed description on the main principles used 
to give a recommendation for BLV or BGV (SCOEL, 2014a).  
BLVs are derived on the basis of currently available scientific data, which indicate that 
concentrations or levels of activity equivalent to the BLV are unlikely to result in adverse effects on 
health. They can be derived in one of the following three ways (SCOEL, 2014a): 
1. When studies in humans (occupational field studies or experimental laboratory studies on 
volunteers) are available, linking adverse effects with concentrations of the chemical or its 
metabolites in biological media, the NOAEL may directly be used to derive the BLV that is 
related to this level. 
2. If such studies are not available but an OEL has been set and studies in humans provide a 
link between airborne concentrations of the compound and concentrations of the compound 
or its metabolites in biological media, a BLV may be recommended in a way that 
corresponds to the OEL. Supporting evidence may be drawn from toxicokinetic modelling. 
This implies that any re-evaluation of an existing OEL must be paralleled by a re-evaluation 
of the corresponding BLV. The two exposure limits (OEL, BLV) are generally based on 
equivalent effects of substances on the exposed worker. 
3. In case of biological effect monitoring, the BLV is directly derived from suitable studies in 
humans. The documentation should then explicitly deal with the question of the adverse 
nature of this effect in view of standard setting. 
Where toxicological data cannot support a health-based BLV (e.g. cases in which no health based 
OEL can be set), a BGV might be established. This value represents the upper concentration of 
the substance or a metabolite of the substance in any appropriate biological medium 
corresponding to a certain percentile (generally 90 or 95 percentile) in a defined reference 
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population. If background levels cannot be detected, the BGV may be equivalent to the detection 
limit of the biomonitoring method, which then is to be specified in the document. 
In 2014, SCOEL published a list of recommended health-based BLVs and BGVs (SCOEL, 2014b), 
which includes BLVs or BGVs for 22 substances, including e.g. cadmium, aniline, MOCA and 
MDA, which have been assigned to the group of the priority compounds within HBM4EU. This 
document has not been updated since then, but after 2014 SCOEL has published 
recommendations on o-toluidine, beryllium, hexachlorobenzene and PAH mixtures containing 
benzo[a]pyrene, which include either a BLV or BGV. For example, in the case of 
hexachlorobenzene, no OEL is proposed but only a BLV since the substance is very 
bioaccumulating, has a low vapour pressure and is well absorbed through the skin (SCOEL, 2016). 
In addition, health effects of hexachlorobenzene could be directly linked to blood levels. Therefore, 
biological monitoring was considered as the only reliable measure to assess occupational 
exposure and health risk. It should be noted that for non-threshold carcinogens (like o-toluidine), 
SCOEL does not propose any health based limit value, therefore, in these cases also for 
biomarkers only BGV can be recommended (SCOEL, 2016). Most of the biological limit or 
guidance values recommended by the SCOEL are based on the measurement of the parent 
compound or the metabolites in urine, some are based on blood levels (e.g. B-Pb) but there are 
also values based on e.g. adduct levels (acrylamide).  
Table 6: Biological limit and Guidance Values recommended by SCOEL for HBM4EU priority 
substances 
Substance BGV BLV SCOEL SUM no 
Aniline  0.2 mg aniline/l urine 153 
Cadmium  2 μg Cd/g creatinine 136 
DBP 70 µg mono-n-butyl 
phthalate/l urine 
 143 
Bisphenol A 7 µg/l  113 
4,4’-Methylene-bis-(2-chloro-
aniline) (MOCA) 
Detection limit of the 
method (end of shift) 
 174 
4,4'-Methylenedianiline 
(MDA) 
1 μg/l urine  107 
o-toluidine (belongs to the 
group of aniline compounds) 
0.2 µg/l  301 
PAH mixtures containing 
benzo[a]pyrene 
0.5 µg 1-
hydroxypyrene in urine 
 404 
As described earlier, none of the SCOEL recommendations on the biological guidance or limit 
values have been taken forward into the legislation. Since there are no EU level BLVs given, it is 
currently up to the Member States how they apply human biomonitoring in the exposure and health 
risk assessment of workers. Practices related to the human biomonitoring vary between different 
countries. These practices in different countries have been surveyed by the questionnaire which 
results are presented in chapter 4.4.4. In addition, DG Employment has recently published a study 
entitled: “Second study to collect updated information for a limited number of chemical agents with 
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a view to analyse the health, socio-economic and environmental impacts in connection with 
possible amendments of Directive 2004/37/EC on the protection of workers from the risks related 
to exposure to carcinogens or mutagens at work (RPA, 2017)”. Also this includes some information 
on the use of biomonitoring in the occupational exposure and risk assessment in the different 
member states.  
 Risk assessment of cosmetics in EU 
In general, the safety evaluation of cosmetic ingredients by the Scientific Committee on Consumer 
Safety (SCCS) 6 is based upon the principles and practice of the risk assessment process usually 
applied for chemical substances in the EU (SCCS, 2016). This risk assessment procedure is 
subdivided in 4 parts:  
1) Hazard identification is carried out to identify the intrinsic toxicological properties of the 
substance, i.e. whether it has the potential to damage human health. It is based on the results of in 
vivo tests (performed before 2013, due to animal testing ban afterwards), in vitro tests, clinical 
studies, case reports, epidemiological studies, data from post-marketing surveillance and in silico 
methods. Intrinsic physical and chemical properties of the substance under consideration are also 
taken into account.  
2) Dose-response assessment: In this part, the relationship between the exposure and the toxic 
response is evaluated. In the case of an effect with a threshold, usually the highest dose at which 
no adverse effects are observed (NOAEL) is determined. A dose without any effect may also be 
observed (NOEL). If the NOAEL cannot be derived, the lowest dose at which an adverse effect is 
observed (LOAEL) may be used. The BMD may be used as an alternative for the NOAEL, NOEL 
or LOAEL value. In the case of non-threshold carcinogens, the BMD or the T25 (chronic dose rate 
that will give 25% of the animal's tumours at a specific tissue site after correction for spontaneous 
incidence) is used as a dose-descriptor. Dose-response assessment is not restricted to in vivo 
data: if sufficiently robust, relevant and justified, also in vitro data could be used on a case-by-case 
basis.  
3) Exposure assessment: In this part, the amount of the substance and the frequency of human 
exposure to the substance are determined (including specific groups at potential risk, e.g., children, 
pregnant women, etc.). Exposure due to cosmetic products is estimated based on exposure 
scenario defined by the SCCS in its Note of Guidance (SCCS , 2016).To calculate the amount of 
cosmetic ingredient applied on the skin, the concentration of the ingredient in the products is 
multiplied by the amount of the cosmetic products used every day. To estimate systemic exposure, 
skin penetration is measured, usually in vitro, in conditions representative of the usual use of the 
products. 
4) Risk characterisation: In the case of a threshold effect, the margin of safety is mostly 
calculated from oral toxicity studies and only in some cases from a dermal toxicity study. Where 
the NOAEL is a dose descriptor for an external dose, the NOAELsys is a dose descriptor for the 
systemic exposure to a substance and is calculated from the NOAEL by use of the proportion of 
the substance systemically absorbed, which can be either based on oral bioavailability data (on 
Caco-2 cells model for example) or by assuming default values for oral bioavailability depending on 
the physico-chemical properties of the ingredient. For non-threshold effects (e.g. a non-threshold 
carcinogenic effect), the lifetime risk is often based on the T25 as above. Alternatively, the margin 
of exposure approach, for instance based on the BMD approach, can be used. 
Human Biomonitoring in the Cosmetic Safety Evaluation 
                                               
6 Website:  
https://ec.europa.eu/health/scientific_committees/stub-for-f2a15b9438331568855209dc941b28691f940f4cc1aec4a7d18df58d_en 
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For cosmetic ingredients, the risk of systemic side effects is determined by the absorption of 
cosmetic ingredient across the skin as estimated by in vitro dermal/ percutaneous absorption 
studies, but also depending on the use of the product and the possibility of oral ingestion 
(toothpastes for example) or exposure by inhalation (spray products for example). If no 
experimental data are available, default values proposed in the SCCS note of Guidance are used 
to estimate the exposure. In case of uncharged small-size lipophilic substances, there may be a 
significant absorption, which may be a cause of concern for low-dose biologically active molecules. 
In that situation, studies measuring the unchanged compound or its metabolite in urine or blood of 
volunteers may be valuable. These studies may provide an accurate estimate of the systemic 
effective dose in humans under in-use conditions by integrating exposure from all routes. They 
may also provide insight into the biotransformation and elimination rate of the substance, i.e. 
toxicokinetic aspects that with the ban of animal studies will be increasingly difficult to document. 
However, as HBM accounts for all sources (air, water, diet, consumer products etc.) and all routes 
of uptake, HBM data as such are not suitable for the assessment of exposure of a (cosmetic) 
substance when other (non-cosmetic) sources for uptake and exposure are involved. They should 
rather be used as support in risk assessment and risk management. Back-calculation from 
biomonitoring data to external exposure data is possible but requires additional information (e.g. 
type of biomarker, exposure modelling).  
If adequately applied (i.e. toxicokinetics and metabolism of a substance is taken into account), 
HBM data can support and complement information on all aspects of ADME of a cosmetic 
substance, which are addressed in the safety evaluation dossier (e.g. results from in vitro and in 
vivo dermal absorption studies, results from toxicokinetic studies). HBM may also complement the 
results of further in vitro methods and animal studies, which are used for hazard and for risk 
assessment. Especially in view of the prohibition of in vivo animal studies on cosmetic substances, 
HBM makes it possible to gain important in vivo information, also directly in humans (no inter-
species extrapolation, limited number of people involved). HBM data can be also combined with 
information from non-animal methods and PBTK modelling to generate more reliable information 
on toxicokinetics and to provide linkages between AOPs and human internal levels. If sufficient 
animal data is available, intraspecies variation can also be addressed using HBM. 
When using HBM in the context of safety evaluation of consumer product ingredients, aspects 
which limit its field of application should be taken into account: 
 HBM is applicable to substances that are systemically taken up and where the half-life of 
the exposure biomarker enables sampling and analytical determination. 
 HBM is not appropriate when the relevant biomarker is an endogenously formed substance, 
present in much higher concentrations than those caused by uptake from the environment 
or consumer products. 
 Various factors influence HBM results, including age, gender, lifestyle, consumer habits, 
diet, place of residence etc. as they modify the amounts of chemical substances taken up. 
Inter-individual differences in the metabolism of chemical substances, excretion of 
metabolites, health status as well as different compositions of biological materials like 
varying dilutions of urine etc., even under identical conditions of exposure, may provide 
different HBM results. 
 Other error sources are contamination of samples during collection and handling of the 
biological samples if no specific metabolite is used as marker 
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HBM4EU priority substances recently evaluated under the scheme 
Prioritised substances were not evaluated yet under the Cosmetic Safety Evaluation scheme.  
HBM data were used in the evaluation of parabens for cosmetic use as supportive data. Results of 
biomonitoring studies were indeed indicating that the (average) systemic exposure dose was 
considerably lower than estimated in the previous paraben opinion for adults who use all types of 
cosmetic products with parabens at the authorised concentrations. Exposure estimates based on 
biological monitoring data were considered, therefore, by SCCS as useful additional information in 
their overall evaluation on the safety of parabens. 
 Risk assessment schemes for mixtures 
The WHO/IPCS (2009) framework for the risk assessment of combined exposure to multiple 
chemicals is a widely accepted framework designed to aid risk assessors in identifying priorities for 
risk management for a wide range of applications where co-exposures to multiple chemicals are 
expected. It is based on a hierarchical (phased) approach that involves integrated and iterative 
consideration of exposure and hazard at all phases. Its use is often hampered by large data gaps 
on exposure as well as hazard information phases, with each tier being more refined (i.e., less 
cautious and more certain) than the previous one, but more labour and data intensive. It includes 
reference to predictive and probabilistic methodology in various tiers in addition to tiered 
consideration of uncertainty.  
Application of the framework (see Figure 2) is not confined to any particular type of chemical or 
effect. However, it is intentionally concise, based on the recognition that more extensive guidance 
on specific technical aspects, including data quality, is available (ATSDR, 2004; US EPA, 2000; 
IGHRC, 2006. The framework is designed to be additionally developed through pragmatic application 
in specific case studies.  
 
Figure 2: A conceptual representation of the WHO/IPCS framework (from Meek et al., 2011) 
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The terminology used in the context of the WHO, IPCS, ILSI/HESI initiatives (Meek et al., 2011; 
IPCS, 2009b) is an important aspect of the framework application. Exposure to multiple chemicals 
is defined as a “combined exposure”, should it be by a single route or by multiple routes (which has 
sometimes been referenced as “cumulative” exposure, e.g. by US EPA, 2003). Exposure to a 
single chemical from multiple sources and by multiple pathways and routes is defined as an 
“aggregate exposure”. Substances grouped together for evaluation of combined exposure are 
referenced as an ‘‘assessment group.” 
Additionally, the “mode of action (MOA)” is an important concept to take into account. A postulated 
MOA is a biologically plausible sequence of key events leading to an observed effect supported by 
robust experimental observations and mechanistic data. It describes key cytological and 
biochemical events—i.e., those that are both measurable and necessary to the observed effect 
(Sonich-Mullin et al., 2001). Combined exposure to multiple chemicals can be defined in the 
context of whether or not the components act by similar or different MOAs in induction of critical 
effects (i.e., ‘‘single MOA or ‘‘multiple MOA). It does not imply full understanding of mechanism of 
action at the molecular level. Chemicals that act by the same MOA and/or at the same target cell, 
tissue or organ often act in a potency-corrected ‘‘dose additive’’ manner. Alternatively, chemicals 
may act independently, by discrete MOAs or at different target cells, tissues or organs 
(independent joint action).  
Methods are based on different approaches on the assumptions of dose additivity (where 
components are considered to be toxicologically similar), response additivity (where components 
are considered to act independently) and interaction (where effects of combined exposure to 
components are expected to be greater than or less than those based on the assumption of dose 
additivity). For dose additivity, approaches are normally based on summed indices of comparison 
of estimated exposure with hazard for components (e.g., the hazard index). Alternatively, they are 
based on summed estimated exposure to components adjusted by potency, relative to an index 
compound (i.e., relative potency factors). 
Human biomonitoring in WHO framework guidance  
The relevance of the HBM in this framework, as in other risk assessment frameworks, is related to 
the problem formulation, Tier 1, Exposure Assessment, where the following questions are raised:  
1. What is the nature of exposure? 
2. Is exposure likely, taking into account the context? 
3. Is there a likelihood of co-exposure within a relevant timeframe? 
4. What is the rationale for considering compounds in an assessment group? 
In relation to question 3) additional information can be triggered which may relate to the use of 
HBM in the context of the evaluation: 
 Do temporal aspects of external exposure, toxicokinetics and toxicodynamics preclude co-
exposure to the compounds of interest? 
 Specifically, do the compounds in the “assessment group” have short half-lives (kinetics) or 
effects of short duration (dynamics)?  
 Also, is the time between initial and subsequent exposures for such compounds sufficient 
so as to preclude co-exposures?  
Exposure assessment (including aggregate exposure assessments) can be conducted at various 
scales, in which only the total exposure is of interest. This is done when using general intake 
fractions (e.g. the intake assessments for food additives) or actual human biomonitoring. In these 
cases, it is not important to know which routes or which products lead to exposure, but only 
whether the exposure is at a certain overall level (order of magnitude). As known, human 
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biomonitoring data may indicate co-occurrence of substances in the human body or elimination 
products. Such data indicate the potential relevance of their consideration in a framework analysis 
for an assessment group. 
As future needs, in the report of a WHO/IPCS international workshop on aggregate/cumulative risk 
assessment (IPCS, 2009b), it is identified that the support of human biomonitoring systems, 
exposure databases and disease registries is also critical in order to provide better data, to guide 
prioritisation of assessments and to evaluate the benefits of cumulative assessments. 
It is also noticed, that the draft framework prepared after the workshop reflects the further 
development of the concepts and includes an “approach to tiered consideration of hazard for 
exposure to multiple chemicals”. It includes subsequent considerations on ADME, common 
metabolite biomonitoring, mechanisms, common molecular target and MOA as depicted in Figure 3. 
Common metabolite biomonitoring (HBM) is increasingly important when going from modified tier 1 
to tier 3. 
 
 
Figure 3: A proposed approach to tiered consideration of hazard for exposure to multiple chemicals 
(from WHO/IPCS 2009b) 
As a concluding remark, there are several EU 2020 Initiatives focusing on the risk assessment of 
chemical mixtures, mostly directed to consumers and general public i.e. EDC-MixRisk, 
http://edcmixrisk.ki.se/, an EU project designed to improve a safer environment for children and 
concerned about their quality of life being threatened by environmental chemicals or their mixtures. 
In this context, risk assessment strategies with inclusion of HBM data and reference values are 
considered more and more relevant to allow estimation of the real body burden of chemical 
mixtures.  
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 Health impact assessment schemes 
 Introduction to Health Impact Assessment (HIA) 
WHO defines an HIA as “a combination of procedures, methods and tools by which a policy, 
programme or project may be judged as to its potential effects on the health of a population, and 
the distribution of those effects within the population” (WHO, 1999). Other definitions also exist. For 
example, the Center for Disease Control (CDC) in the US for example sees an HIA as a systematic 
process that uses an array of data sources and analytic methods, and considers input from 
stakeholders to determine the potential effects of a proposed policy, plan, program, or project on 
the health of a population, but also whether the health effects are distributed evenly within the 
population. An HIA may be part of an environmental impact assessment in case the health topic is 
dealt with in the assessment. In terms of policy, an HIA is a tool to promote health within all 
policies. It helps decision-makers to make choices about alternatives and improvements to prevent 
disease/injury and to actively promote health. Within this context it is important to consider the 
definition of “health” used in the HIA. Most often, HIAs are used in the public health domain (e.g. 
described by the WHO) and health is defined in holistic terms, including social and mental well-
being and not only the absence of disease or infirmity. The socio-environmental model of health by 
Dahlgren and Whitehead (1991) is usually used. In this concept, where health is defined by both 
biophysical and social factors. The aims of HIAs based on the model of Dahlgren and Whitehead 
are: 
 To reduce or eliminate negative health impacts and maximise the positive health impacts of 
policies, programmes or projects. 
 To reduce health inequalities. 
While there is no single agreed method for an HIA, a general pattern has emerged amongst 
methods (Sweden: FHI, 2005; United Kingdom: Herriott and Williams, 2010; Ireland: Metcalfe et 
al., 2009) and there is much overlap between the various methods. Figure 4 gives an overview of 
the different steps which should be followed in an HIA by WHO. Sectors in which HIAs are applied 
according to WHO are for example transport (effect of air pollution, noise, accidents, active 
mobility), food (use of pesticides), waste management (exposure to chemicals) and energy 
production (air pollution). 
 
Figure 4: HIA procedure according to WHO (http://www.who.int/hia/tools/en/) 
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Different steps in HIA explained in brief: 
1) Screening: Description of policy, plan, program or project; Questioning whether it affects 
health; Questioning whether the whole population is affected or vulnerable groups; Decide 
if HIA is necessary and possible; Rapid or comprehensive HIA;  etc. 
2) Scoping: Identify what to do and how to do it and who will do it; Setting aims and 
objectives; Which evidence should be collected; Search for evidence (interviews, in depth 
reviews, off the shelf evidence, surveys, etc.); Setting boundaries; Involvement of 
specialists; Setting up focus groups; Potential health impacts which should be investigated; 
etc. 
3) Appraisal: Large amount of HIA work is carried out in this step: assessment of health 
impact using available evidence; Baseline, predictions, mitigation, significance, uncertainty; 
etc. 
4) Reporting: Developing recommendations to reduce hazards and/or improve of health. A 
key output of HIA is the set of recommended changes to the proposal. 
5) Monitoring: Monitoring the implementation of the proposal to ensure that any 
recommendations that decision-makers agreed upon, actually occur; As with any 
intervention, evaluation is required to see if it has worked is required 
 HIAs in toxicological risk assessment and environmental epidemiology 
Within the toxicological and epidemiological framework, an HIA is more focussed on the 
description of absolute changes in (sub) clinical effects due to a policy measure and focusses less 
on health inequalities, stakeholder appraisal, perception, distribution effects and the maximisation 
of positive health impacts due to policy. The steps taken when performing HIA within a more 
toxicological and epidemiological context do not differ significantly from the WHO HIA procedure 
(for additional information see Figure A1 in Annex A).  
When estimating the impact of air pollution on health, HIA is generally used. Well-known projects 
are APHEIS and APHEKOM7, in which the impact of air pollution on health in 25 European cities 
was assessed (Medina et al., 2009). Also at  the EU level HIA is used to calculate different air 
pollution scenarios and to set goals for air pollution reduction: EU Clean Air Package (IIASA et al., 
2014; Holland, 2014). For energy production at the EU level, HIA is also often used to calculate the 
impact of different energy systems on health (Bickel and Friedrich, 2005; CASES project8). Dose-
response or exposure-effect curves are mainly based on external exposure to air pollution 
(particulate matter).  
Results from a human health risk assessment (Hazard identification -> dose-response assessment 
-> exposure assessment -> risk characterisation) can be used within an HIA to predict human 
health effects of specific exposures. However, several uncertainties arise with the extrapolation of 
human health risks to human health effects (being at risk does not equal having a health effect).  
Two indicators used by the OECD and the EU for presenting health impact among the general 
population are DALYs (Disability Adjusted Life Years) and external costs, however in an HIA it is 
not obligatory to make such extended calculations. Other indicators or calculations are valid as 
well. In the framework of European Environmental Burden of Disease (EBD) studies, the health 
impact (DALYs) of 9 stressors was calculated in a consistent way (as far as possible) in 6 EU 
countries (Belgium, Finland, France, Germany, Italy, the Netherlands) (Hänninen et al., 2011). 
Considered stressors were: particulate matter, second hand smoke, radon, traffic noise, lead, 
                                               
7 http://aphekom.org/ 
8 Cost Assessment for Sustainable Energy Systems: http://www.feem-project.net/cases/downloads_deliverables.php 
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ozone, dioxins, benzene and formaldehyde. When calculating the impact of dioxins different 
exposure data were used, depending on available data. Different ways to estimate daily intake of 
dioxins and dioxin-like PCBs were surveys on food consumption, total diet studies, human 
biomonitoring (investigation of human milk and blood levels). For lead, the health impact in terms 
of DALYs due to IQ loss in children and blood pressure elevation in adults was calculated based 
on Pb body burden results: blood lead levels (Hänninen et al., 2011). Similarly, Remy et al. (in 
preparation), estimated the reduction in external costs related with decreasing human lead levels 
over time in Flanders, Belgium. 
 Role of human biomonitoring in HIA 
Within an integrated environmental HIA framework (see Figure A2 in Annex A), HBM serves as a 
pivotal point between environment and health, on the one hand leaning on environmental data to 
provide information on sources and pathways of exposure, and on the other hand clarifying 
hypotheses on the relationship between internal dose and prevalence of disease clusters 
(INTARESE: Integrated Assessment of Health Risk of Environmental Stressors in Europe: Briggs, 
2008; Smolders et al., 2009; Liu et al., 2012).  
Human biomonitoring is not commonly used in HIA. Often HIA include the application of dose-
response or exposure-effect curves in which exposure is external exposure to pollutants or 
exposure based on environmental sources. The use of internal exposure through HBM could lead 
to a refinement of exposure information as accurate information on integrated personal exposure is 
provided. HBM data have proved to be a valuable addition to, or have even surpassed, estimates 
of exposure based on environmental measures (Suk et al., 1996; Bates et al., 2005). In the 
following paragraphs some examples are given on the uses of HBM data in HIA. 
The WHO estimated the health impact of mercury through neurodevelopmental toxicity. The 
disease burden was addressed using the distribution of hair mercury concentrations of pregnant 
women or women of childbearing age as a measure of infant exposure. The rate of mild mental 
retardation caused by methylmercury-related IQ loss and the resulting number of DALYs lost were 
calculated from the exposure distribution (Poulin and Gibb, 2008). Similarly, the health impact of 
chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe was estimated based 
on mercury hair and urine concentrations (Steckling et al., 2014). 
A recent WHO study investigated the burden of disease of foodborne chemical toxins, including 
dioxin and dioxin-like compounds. The results of the breast milk concentrations (exposure 
assessment) and BMD analyses (toxicity assessment) from 50 countries were compared, taking 
account of possible differences between experimental animals and humans, as well as intra-
individual differences among humans. This comparison provided country-specific estimates of the 
incidence of dioxin induced prenatal and postnatal hypothyroidism and impaired fertility. It was 
calculated that dioxin exposure alone globally leads to 3 (3–20) DALYs in 100.000 people (Gibb et 
al., 2015). 
In the US, Lanphear et al. (2005) performed a large scale study on the association between 
intelligence test scores and blood lead concentrations, especially for children who had blood lead 
levels under 10 μg/dL. To this end, they examined data collected from 1,333 children who 
participated in seven international population-based longitudinal cohort studies. The lead levels 
were determined in venous or fingerstick capillary blood samples and cord blood lead in a 
subsample of the subjects. The primary outcome was the full-scale IQ, which is a composite score 
of verbal and performance tests. The lead-associated IQ deficits observed in this pooled analysis 
were significantly greater at lower blood lead concentrations. The larger sample size of the pooled 
analysis permitted the authors to show that for a given increase in blood lead, the lead-associated 
intellectual decrement was significantly greater for children with a maximal blood lead 
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concentration of < 7.5 μg/dL than for those who had a maximal blood lead concentration of ≥7.5 
μg/dL.  
In the studies of Trasande et al., external costs (non- internalised costs or costs for society) were 
calculated for the exposure to endocrine disruptors (EDCs) in Europe based on HBM data 
(Trasande et al., 2015; Legler et al. 2015). According to their calculations EDC exposures in the 
EU contribute substantially to obesity and diabetes, with a moderate probability of €18 billion costs 
per year (this was considered as a conservative estimate by the authors). However, since the 
evidence on the association between EDCs and these diseases in humans is still debatable, these 
EBD risks and cost calculations include severe uncertainties even though population biomonitoring 
data based exposure estimates can be considered reliable.  
Recently Tobolik et al. (2016) presented the start of the UKAGEP project in Germany. This project 
aims at estimating the EBD of 16 risk factors for children aged between 3 and 17 years in 
Germany. Current HBM data derived in the population-representative German Environmental 
Survey (GerES V, 2014-2017) are used to estimate the internal exposure of German children for 
eight hazards (e. g. lead in blood, arsenic in urine, EDCs in urine). Combined with exposure-
response functions, which are derived or updated by meta-analysis, and data on the related health 
effects, DALYs will be calculated.  
Another useful approach of HBM data for impact assessment is the comparison of HBM effect 
biomarker data (birth weight, eosinophil count, etc.) with health based RVs (from occupational 
exposure, medical data, reference groups). They allow to visualise whether there is any concern 
with regard to health-based criteria, how time trends look relative to these reference values and if 
population groups differ in their proportion above or below the values (FLEHS I, 2006; Engel et al., 
2014). 
 Survey: National risk and HIA practices and the views of risk 
assessors on the use HBM in risk assessment 
 Aims of the survey 
The ultimate goal of this task is to improve human risk assessment by more efficient application of 
HBM. In order to achieve this goal, the current risk assessment practices in different countries (EU- 
and non-EU countries) and the current use of human biomonitoring in the risk assessment of 
chemicals were evaluated using a questionnaire to national risk assessors. The aim was to find out 
how familiar risk assessors working in different field of chemical risk assessment are with HBM, 
how they find the use of HBM in risk assessment, what are the main reasons and obstacles for 
using HBM in health risk assessment and HIA. 
The questionnaire was conducted in summer 2017 using a web-based tool Webropol 
(www.webropol.com). It was divided in two parts; first part was targeted for risk assessment in 
general (under e.g. chemical, pesticides and food safety legislations) and the second part was 
targeted specifically to the use of biomonitoring in occupational health. This division was made 
since biomonitoring has long traditions in occupational health and safety as a tool for workplaces 
and occupational health care to assess the exposure and risks, and the role of national OSH 
authorities is only to provide guidance for its use at workplaces. It was also clear that national 
practises related to its use in OSH are likely to vary since the current EU legislation gives very little 
guidance for its use. The first part included questions both on risk and HIA, the second part 
addressed only the use of HBM in the risk assessment at workplaces. 
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 Respondents 
There were 71 respondents from 18 EU countries, 2 non-EU countries in Europe that participate in 
HBM4EU and 5 non-European countries (Figure 5 and Figure 6). For 4 out of 71 respondents, the 
country was not indicated. Furthermore, about 50% of the EU respondents were located in just 5 
EU countries. This means that extrapolation and generalisation of the results of this survey needs 
to made by caution; especially for those questions that had a limited number of respondents. 
 
Figure 5: Responses from European and non-European countries (N=71) 
 
Figure 6: Country distribution of responses (N=71) 
The most abundant regulatory areas the respondents are active in were REACH, OSH and the 
food safety domain (each >30%) (Figure 7). 23% of the respondents were working only in the OSH 
domain, and responded only to the second part of the survey. 
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Figure 7: Regulatory areas of the respondents (N=71) 
 Results: Use of HBM in risk and health impact assessment  
The first part of the questionnaire was related to the use of HBM in risk and HIA in general, 
including different risk assessment frameworks, like REACH, food safety, cosmetics, pesticides 
etc. Out of 55 respondents, only 27% replied that HBM is regularly applied in their regulatory 
domain in their country (Figure 8). Thus, in most cases it is either not used or used only to limited 
extent. Those who answered that it is used only in limited extent mentioned incidental HBM 
campaigns such as following an incident (i.e. independent of regulatory framework), societal unrest 
(like recently with PFOA around the Chemours (previously DuPont) factory in Dordrecht in NL or 
pertaining to only one chemical, i.e. Pb, for which HBM is obligatory by law under OSH framework.  
 
Figure 8: Use of human biomonitoring on general population (N=55) 
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With respect to guidance for the use of HBM for risk assessment in their country, out of 55 
respondents, >60% responded that no guidance is available (Figure 9). In case there is guidance 
available, it is usually specific for a single regulatory domain: REACH, Cosmetic Product 
Regulation, OSH, small scale incidents handled by local environmental health services or e.g. for 
Pb in workers. In open comments it was mentioned that even if e.g. REACH guidance refers to 
biomonitoring, more guidance on its use in risk assessment is needed. Also for the technical and 
organisational application of HBM it became clear that guidance is largely missing (Figure 10).  
 
Figure 9: Existence of guidance for the use of human biomonitoring data for risk assessment on 
general population (N=55) 
 
Figure 10: Existence of specific guidance for the technical and organisational application of HBM on 
general population (N=55) 
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Main drivers to start HBM are (50 respondents) to confirm exposure (54%), assess internal 
exposure level (52%), and to support risk assessment and define priorities for intervention (50%) 
(Figure 11). Although health surveillance is the one of the main drivers in occupational 
biomonitoring (see next chapter), in other risk assessment fields exposure assessment and priority 
setting are more emphasised. 8 respondents out of 50 (16%) responded that HBM is not usually 
performed for this question, whereas for a very comparable question (Figure 8) 21 out of 55 
respondents (38%) responded that HBM is not usually performed. This difference is most likely 
explained by the way how questions were phrased; even though HBM is not usually performed in 
the respondents’ country, he/she may have selected drivers on the basis of some infrequent cases 
in which biomonitoring has been used. 
 
Figure 11: Main drivers to start human biomonitoring campaign in general population (N=50) 
When questioned how HBM might contribute best now and in the near future to risk assessment 
and management, the following answers were given: realistic exposure data, aggregating routes of 
exposure, risk management prioritisation (policy, intervention), comparing subpopulations and 
identifying vulnerable populations. According to the respondents, DNA and protein adducts are not 
widely used as exposure biomarker (20%) and effect biomarkers are only marginally used (10%). 
From the answers it appeared that in addition to existence of validated methods for biomonitoring, 
existence of health-based limit or guidance values and the ability to relate biomarker levels to 
external exposure were judged of most important criteria to be met before HBM can be used in the 
risk assessment. However, no large difference to other possible criteria, i.e. ability to estimate 
biological equivalent (BE, Hayes and Aylward, 2009), existence of HBM RVs, a sufficient 
population size, and relation biomarker of exposure to health effect were observed (Figure 12). 
Additional linked points mentioned in the comments were appropriate knowledge about ADME and 
the appropriate metabolite to monitor as well as appropriate size of relevant sub-populations (men 
and women, children, pregnant women). It appears from the responses given that the criteria set 
upfront are often not met. 
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Figure 12: Criteria for using human biomonitoring data in risk assessment on general population 
(N=51) 
According to the responses received, generally in risk assessment frameworks, HBM data is not 
compared to any health based limit or guidance values nor to HBM RVs (population distribution 
based guidance values). This most probably reflects the fact that there are only few limit values for 
general population, with the exception of German HBM I and II values or biological equivalents 
published for some substances in literature. This differs from the OSH framework where there are 
BLVs/BGVs or RVs available for commonly biomonitored substances. In the open responses 
German HBM I and II values were mentioned. Next to this, some internal (laboratory, institutional, 
like BEs by Summit Toxicology) recommendations approaching the status of guidance values were 
indicated. Furthermore, EFSA has published some epidemiologically-based guidance values, such 
as for B-Pb. Also with respect to Cd, there is a biomonitoring guidance value regarded as safe by 
EFSA and expressed as urinary Cd level. For contaminants in food, HBM levels are compared with 
levels used as basis for setting TDIs at EFSA.  
When no national BLV or BGV were available mostly values from other countries are used. But as 
noted earlier, in many countries HBM for the general population is rarely used. 
Only a small part of 53 respondents mentions ongoing work to elaborate health-based limit values 
for biomarkers. Majority of the respondents does not know if there are these kind of activities going 
on in their country. Also on those experts working in the field of OSH, less than half recognises 
these activities in their country. 
The three most important obstacles (Figure 13) for applying HBM data in risk assessment 
mentioned: 
 No official guidance for HBM use 
 No legal enforcement 
 No guidance values or background/normal values 
Related to the absence of health-based guidance values or population-based RVs, also an inability 
to interpret or use HBM data was raised rather high. Whereas in the OSH field (see next chapter) 
ethical aspects were raised, in risk assessment under other frameworks risk for public 
arousal/anxiety when real internal exposure becomes evident was ranked higher. 
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Figure 13: Obstacles faced when applying biomonitoring data in the risk assessment of general 
population (N=39). Question was asked on the following specific substance groups: Chemicals (in 
general), Phthalates/DINCH, Bisphenols, Per-/Polyfluorinated compounds, Flame Retardants, Cd/Cr, 
PAHs and air pollutants, Anilin family, e.g. MOCA, Chemical mixtures (pesticide mixtures), Emerging 
chemicals 
The answers were given HBM4EU priority substance group specific and subsequently cumulated 
per obstacle. So no quantitative data interpretation is feasible, nevertheless, the above mentioned 
obstacles seem to be the most important general ones. 
Except one, all 34 respondents confirmed that when it is possible to perform a HIA based on HBM 
data, it could be of additional value to assess certain policy goals prospectively and retrospectively. 
Many examples are given: phthalates, PFAS, Pb, arsenic, hexachlorobenzene. 
According to the respondents, communication of HBM data in the general population is best done 
to the participants personally as well as within the health care system and obviously, to the national 
authorities involved in health programs. 
 Results: Use of HBM under occupational health and safety legislation 
There were 28 respondents who responded in the second part of the questionnaire focused on 
occupational health and safety. Five of them were from non-EU countries and two without 
background information. 
HBM is regularly done in different countries within the occupational safety and health interventions 
(56%, n=27). However, 44% responded that it is either not used or it is used only in a limited 
extent. In this case the answer was justified due to the fact that biomonitoring is legally required 
only when monitoring exposure to lead. Thus, regulation clearly facilitates the HBM appliance. 
Most of the respondents (73%, n= 26) indicate that there is guidance (regulatory, institutional) for 
the use of human biomonitoring in the risk assessment at workplaces (Figure 14). Only three of 
them (all representing different countries) said that there is no guidance in their country. 
 
D 5.1 - Human biomonitoring in risk assessment  Security: Public 
WP 5 - Translation of results into policy Version: 2.0 
Authors: Tiina Santonen Page: 52 
 
 
Figure 14: Existence of guidance (regulatory, institutional) for the use of human biomonitoring in the 
risk assessment at workplaces (N=26) 
The main drivers to perform human biomonitoring at occupational settings were Health 
Surveillance performed by occupational health care and the existence of Regulations (e.g. B-Pb 
measurements required by law)” (67%, n=27), followed by the assessing the magnitude of internal 
exposure to a substance (52%) and confirming exposure to a specific substance (48%) (Figure 
15). However, although the main driver to perform biomonitoring at workplaces is health 
surveillance made by occupational health care, only 37% of the respondents (n=24) indicate that 
the biomonitoring data is available for use in exposure assessment and management at the 
workplace (Figure 16). 
Thus, the results of the biomonitoring in many cases are used only for individual health risk 
assessment and not for the workplace risk assessment and management, which is the 
responsibility of the employer. A reason for this, as mentioned by several participants, is the 
privacy concern. But, although personal data is often protected, group/ aggregated results could be 
used in many cases to review the risk assessment (e.g. identify high exposure situations).  
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Figure 15: The main drivers to perform biomonitoring at occupational settings (N=27) 
 
Figure 16: The availability of the biomonitoring data for use in exposure assessment and 
management at the workplaces (N=24) 
Most of the respondents (77%, n=26) stated that there is guidance for the application of human 
biomonitoring in workplaces/occupational health care (Figure 17). However, when asked about the 
most important obstacles when using biomonitoring in risk assessment, lack of official guidance 
were the second important obstacle, just after the lack of legal enforcement (Figure 19). To the 
question on the effectivity of the regulations, most of respondents (69%, n=26) answered that the 
regulation is not effective enough to support the use of human biomonitoring in occupational health 
and safety (Figure 18). 
Lead was again mentioned by several respondents as an exception since there is a specific 
regulation that supports HBM in case of occupational exposures to lead. Still related with this 
issue, for 17 respondents, lead was the substance mentioned more frequently for which there is a 
BLV or a BGV and most of the respondents (59%, n=22) stated that the values are binding limits 
given by the law. Ethical aspects like acquiring informed consent were surprisingly raised rather 
high when the data on the obstacles related to the chemicals in general were analysed separately 
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(data not shown). This is surprising when taking into account that human biomonitoring has long 
traditions in occupational health. 
 
Figure 17: Existence of guidance for the application of human biomonitoring in 
workplaces/occupational health (N=26) 
 
Figure 18: Effectivity of regulations to support the use of biomonitoring in occupational health and 
safety (N=26) 
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Figure 19: Obstacles faced when applying biomonitoring in occupational risk assessment (N=19). 
Question was asked on the following specific substance groups: Chemicals (in general), 
Phthalates/DINCH, Bisphenols, Per-/Polyfluorinated compounds, Flame Retardants, Cd/Cr, PAHs and 
air pollutants, Anilin family, e.g. MOCA, Chemical mixtures (pesticide mixtures), Emerging chemicals 
More than half of the respondents (58%, n= 26) do not recommend the use of DNA or protein 
adduct analyses as a marker of exposure in occupational biomonitoring. Furthermore, only about 
one third of the respondents (35%, n=26) recommend the use of a biomarkers of effect (including 
e.g. “omics”- based biomarkers) in occupational biomonitoring. However, also 15% of the 
respondents mentioned “I don’t know”, which most probably reflects the fact that there are currently 
only few relevant, validated effect markers available. 
Regarding the criteria for using human biomonitoring data in risk assessment, most of respondents 
answered that the existence of health based biological limit/guidance values (BLVs/BGVs) (96%, 
n=26) is the main criteria, together with the existence of validated method for human biomonitoring 
(92%). These were followed by the information on that HBM level can be related to the exposure 
source (85%) (Figure 19). Approximately half of the respondents (54%, n= 26) stated that 
biomonitoring results of workers are compared to occupational BLVs or BGVs. 
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Figure 19: Criteria for using human biomonitoring data in risk assessment at workplaces (N=26) 
44% of the respondents (n=25) stated that there is work going on to elaborate health based limit 
values for workers. However, 24% do not know if there is any action being developed concerning 
this issue. 
Majority of the participants (68%, n=25) stated that occupational biomonitoring data is usually 
communicated to the Occupational Health Service, to the worker (60%) and also an overview of 
the results is communicated directly to the employer (44%) (Figure 20). Regarding this last aspect, 
50% of the respondents (n=18) stated that the occupational health service have an obligation to 
give an overview of the biomonitoring results to the employer (Figure 21). However, 22% do not 
know if this is a reality or not. The way this information is presented to the employer is also very 
diverse since all participants (n=9) responding to this question expressed different forms for 
presenting this information. 
 
Figure 20: Communicating biomonitoring data of workers (N=25) 
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Figure 21: Obligation of occupational health service to give an overview of the biomonitoring results 
to the employer (N=18) 
 Discussion and general findings 
Most participants were from EU countries. Nevertheless, the frequency of respondents from a 
specific EU country varied from 0 to 8. About half of the respondents from the EU were from only 5 
EU-countries. Therefore, care should be taken when generalising the results of this survey. 
However, in some cases results as obtained from the survey were traced back to individual 
countries in order to ensure that some specific results do not only represent a situation in single 
country. 
Taking the uncertainties around the representativeness of the respondents for the whole of Europe 
taking into account, the following more general findings can be taken forward within HBM4EU:  
 HBM is mostly used under OSH framework, less under other risk assessment frameworks. 
However, also under OSH, the use of human biomonitoring is sometimes limited only to B-
Pb which is legally binding. 
 Outside the OSH domain, HBM is often incident driven (regulatory framework independent).  
 Key obstacle for using the HBM instrument is the lack of guidance. This pertains both to: 
o The more scientific part of HBM (what biomarker to measure (parent substance or a 
metabolite), relation between exposure biomarker and most relevant adverse health 
effect, sufficient sampling size including size of subpopulations) 
o The technical and organisational part (not specified in the survey but very likely 
relating to validated sampling and analytical methods, how and to whom to 
communicate the results of HBM). 
 Although under OSH framework most of the respondents noted that there is guidance 
available, also in this case it was considered that lack of guidance is one of the key obstacles.  
 Another key obstacle was the lack of legal enforcement followed by the lack of guidance/limit 
values. Under OSH, also ethical aspects were raised. 
 Under OSH, main drivers to perform human biomonitoring are the regulations and health 
surveillance. Regulations were, however, not considered sufficient by most of the 
respondents. Since biomonitoring is commonly done by occupational physicians as part of 
health surveillance, the results of it are not necessarily effectively used for the exposure/risk 
assessment and management at workplace because of the privacy concerns. 
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Sometimes, open question responses are more or less clearly linked to the EU or even to a 
specific EU or non-EU country. Further elaboration would most probably benefit from further 
discussion of these findings with the National Hub Contact Points (NHCPs) and in some cases 
further elaboration in connection with the NHCPs. It is also noted that responses to open questions 
contained some seemingly important references that could be useful for further work within 
HBM4EU Task 5.3. The full statistics to the survey are attached as Annex to this deliverable report. 
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5 Use of HBM in risk assessment – 1st substance group 
specific risk assessments 
 REACH risk assessment scheme 
 Phthalates  
 Restriction dossier 
A restriction proposal was submitted by Denmark in 2011 to restrict the placing on the market of 
certain articles containing 4 phthalates (DEHP, BBP, DBP and DIBP).  
ECHA’s Risk Assessment Committee (RAC) and Socio-Economic Analysis Committee (SEAC) 
adopted opinions not supporting the proposal. A new proposal from ECHA and Denmark built on 
the previous restriction proposal was submitted in April 2016, presenting additional information and 
assessment covering the hazard, new information on exposure (especially DEMOCOPHES 
biomonitoring data), additional data on costs and trends in substitution, and a review of new 
information on benefits (ECHA, 2017c).  
The exposure assessment has been based especially on DEMOCOPHES urinary biomonitoring 
samples taken in 2011-12 given that it is recent, consists of a large sample size, and is more 
representative for EU28 than all other human biomonitoring studies available, which are the criteria 
that determine the relevance of using HBM data. Morning urine samples were collected from 
mother-child pairs in 16 EU Member States and Switzerland from September 2011 until February 
2012.  
 Some observations could be drawn from the DEMOCOPHES biomonitoring exposure 
estimates, also from information available from Austria, France and Spain and from many 
other studies reporting urinary metabolite levels of the 4 phthalates, as the GerES IV (Koch 
et al., 2007; Becker et al. 2009), a retrospective study on 24h-urine samples from the 
German Environmental Specimen Bank (ESB) (Göen et al., 2009) and a Danish mother-
child pairs study (Frederiksen et al., 2013),exposure of children is higher than that of 
mothers  
 exposure to phthalates has declined over time when older biomonitoring studies are 
compared to the DEMOCOPHES data. 
 based on several studies which measured urinary levels of phthalates together with diet 
change (fasting or low-phthalate diet) or measurement of the content of phthalates in the 
diet, it is assumed that 75% of the intake of DEHP is attributable to food (incl. drinks), 
whereas for DBP, DIBP and BBP it is assumed that 25% is attributable to food. 
 Participants of DEMOCOPHES who reported to have PVC flooring or walls in their homes 
showed significantly higher BBP and DIBP metabolites in children as well as mothers and 
significantly higher DBP metabolite concentrations in children 
One source of uncertainty in the estimates is the use of morning spot samples. This might 
underestimate exposure to the phthalates, as observations have shown that DEHP metabolite 
concentrations are higher in the evening than in the morning. It was also shown that within day 
variability was greater than between day variability, as was within person variability compared to 
between person variability. 
The overall conclusion of the risk assessment based on the biomonitoring data (together with 
exposure modelling) points out that the identified risk to the general population is not adequately 
controlled and needs to be addressed. Indeed, based on the 95th percentile of combined exposure 
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to the 4 phthalates measured from human biomonitoring data, a risk were identified for children in 
13 out of 15 Member States and for women in 6 out of 15 Member States. Overall, in 14 out of 15 
Member States more than 5 percent of the children were at risk. Approximately 5% of new born 
boys (130 000) were at risk through in utero exposure in 2014 and about 16% boys (400 000) were 
at risk from direct exposure in 2014 (ECHA, 2017c). 
Therefore, the proposed restriction targets the risks from exposure to the 4 phthalates by restricting 
their concentration in articles which have the highest contribution to exposure. Further follow-up of 
phthalate levels in general population will bring valuable information on the effectiveness of this 
restriction for the whole of Europe. Further assessment could take into account also the levels of 
other, less regulated phthalates.  
Regarding the human HIA, Denmark considered that there was a lack of sufficient scientific evidence 
from the available human biomonitoring and epidemiological data for the development of dose-
response relationships. Therefore, the benefits associated with reduced exposure to the four 
phthalates are not quantified in the dossier. Nevertheless, to illustrate the magnitude of these 
impacts Denmark evaluated and monetised the impacts based on all evidence available on exposure 
and observed effects (male infertility, cryptorchidism, and hypospadias) i.e. from animal studies, 
epidemiological data and evaluations from recent published reports on the disease burden of EDCs 
as well. The dossier submitter thus monetised benefits using the aetiological (attributable) fraction 
approach as an indication of the magnitude of the human health benefits expected, mentioning that 
considerable human benefits remain not monetised. 
 Opinion on the Application for Authorisation for DEHP used in formulation in 
compounds, dry-blends and Plastisol formulations (ECHA, 2015e) 
Human biomonitoring data used by the applicants were judged of limited informative value, 
because they were not recent and because of their limited geographical coverage. Also, none of 
the HBM studies were reporting specific RMM, thus limited information concerning the level of risk 
management measures and operational conditions at the monitored workplaces were available. 
 Opinion on an Application for Authorisation for DBP used as an absorption 
solvent in a closed system in the manufacture of maleic anhydride (ECHA, 
2014b) 
Regarding the exposure assessment, an oral intake of DBP was calculated by RAC based on the 
90th percentile of exposure estimates from urinary biomonitoring data of the applicant’s workers. 
Regarding the risk assessment, RAC calculated an RCR for workers using HBM data. RAC 
concluded that for this specific use of DBP, the health risk to workers (specifically reproductive 
toxicity) is adequately controlled. 
 Bisphenol A  
 Restriction dossier for BPA 
A proposal to restrict BPA because of health risks for pregnant workers and consumers exposed to 
it in thermal paper - for example when they handle cash register receipts was submitted by the 
French authorities in May 2014.  
France based its hazard assessment of BPA on the effects on several human health endpoints 
(the female reproductive system, the brain and behaviour, the mammary gland, metabolism and 
obesity). The effects on the mammary gland were considered the most critical endpoint, prevailing 
over the others. They were used to calculate the DNEL. At the time of the elaboration of the 
proposal, biomonitoring data evaluating specifically exposure through thermal paper were not 
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available (neither for workers nor for consumers). Thus the development of a BPA exposure 
scenario was proposed through the handling of thermo-printed receipts for workers (cashier) and 
the consumer and the human health assessment was based on the calculation of the disease 
burden for the effects of concern from modelled exposure data only. 
RAC considered that the critical studies selected by France to calculate the DNEL did not allow 
quantification of the dose-response relationships and showed uncertainties. Therefore, for the 
purposes of calculating an oral DNEL, RAC selected the effects on the kidney and, as the available 
data indicated that kidney effects are not the most critical effects of BPA, applied an additional 
assessment factor of 6 to take account of the other endpoints in the overall hazard assessment. 
Since the restriction proposal was concerning the dermal route of exposure due to handling 
thermal paper, a DNEL for the dermal exposure route was also calculated for workers and the 
general population.  
As regards exposure, RAC refined the assessment and complemented it with new biomonitoring 
information on cashiers’ exposure to BPA. The analyses of biomonitoring studies performed by 
ANSES and by EFSA (EFSA, 2015) were included into an updated version of the restriction 
dossier. It appears however that the conclusions were different, mainly due to differences in 
assumptions and methods used as for example on the limit of detection of the unconjugated form 
of BPA in the plasma or on the credibility of studies considering lack of information with respect to 
sample collection and handling (ECHA 2015f). But, the HBM studies were indicating that “the 
cutaneous route of exposure from thermal paper sources was not negligible, based on the 
significant increase of urinary concentrations measured after testing cashiers during exposure 
scenarios”. Applying this methodology, RAC concluded that the risk for consumers is adequately 
controlled but confirmed the risk for workers.  
Regarding the uncertainties in the risk characterisation, RAC indicated that the exposure estimates 
for consumers carry relatively few uncertainties, in part, because HBM data are confirming that 
exposure does not exceed the DNEL. The confidence about a correct conclusion is thus relatively 
high. RAC concluded that the risks from BPA in thermal paper to human health were adequately 
controlled for consumers across the EU (ECHA 2015b). Regarding workers, RAC indicated that the 
available HBM data were scarce and of limited nature, thus providing a lower confidence level to 
the modelling results when compared to consumer exposure. However, as the integrated 
assessment of worker exposure performed is based on both modelling data and available human 
biomonitoring data, reasonable consistency is given since HBM data was largely supporting 
probabilistic modelling. RAC used the BE approach presented by Krishnan et al (2010) to convert 
urinary BPA levels as intakes. RAC concluded that the risks from BPA in thermal paper to human 
health were not adequately controlled for workers across the EU, and that measures to minimise 
exposure were to be implemented on an EU-wide basis (ECHA, 2015b).  
Although human biomonitoring data were published, the dossier submitter and SEAC couldn’t 
update the impact assessment on BPA, because in accordance with the conclusion of RAC, the 
available data did not allow a quantification of the dose-response relationship for the health effects 
of BPA. SEAC didn‘t use the benefit estimates presented in the French dossier but used instead 
expert judgment to determine the likelihood of observing an occurrence rate for each endpoint. 
It has to be mentioned that interpretation of HBM data on BPA is not easy, as the biomonitoring 
studies are showing large fluctuations in urinary concentrations of BPA depending on the type of 
diet. Studies also clearly show that due to the rapid elimination of BPA from the body, the urinary 
concentration of BPA in the individuals is only representative of recent exposure (hours preceding 
the sample only). The urinary sampling also shows high variability, and while collection over 24 
hours significantly represents the quantity of BPA excreted daily, it does not reflect the hourly 
excretion. One additional uncertainty was also related to the assumed higher proportion of BPA in 
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the blood after the dermal exposure when compared to oral exposure because of the by-passing of 
the first phase metabolism in liver. To account for this uncertainty a default assumption was used, 
which leaves room for refining the assessment when new information on the toxicokinetics of BPA 
after dermal exposure appears. 
 Perfluorooctanoic acid (PFOA) and PFOA-related compounds 
 Assessments on PFOA 
REACH restriction dossier for PFOA 
PFOA is a key compound within a larger group of substances, the per- and polyfluorinated 
substances (PFASs). Being a persistent, bioaccumulative and toxic (PBT) chemical, PFOA was 
recognised as a SVHC under REACH back in July 2013. There are also other PFASs that can 
degrade to PFOA in the environment, and are referred to as PFOA-related substances. These 
substances are therefore also included when determining the risk to human health posed by 
PFOA.  
There are ongoing discussions on the appropriate POD for derivation of a DNELbiomarker for the 
general and the worker population respective HBM values for PFOA the current values differ 
among orders of magnitude. Below, the restriction proposal as prepared by Norway and Germany 
in 2016 as well as the subsequent opinion as published by ECHA’s RAC are described. 
Restriction proposal by Norway and Germany 
A restriction proposal report was prepared by Norway and Germany in 2014 (Annex XV Proposal 
for a Restriction –PFOA, PFOA salts and PFOA-related substances; ECHA 2014c). Data from 
various research reports and studies alongside industry surveys by OECD were used to derive 
DNELbiomarker–values for workers and the general population, to calculate external and internal 
exposures, and to assess risk to human health. In the restriction proposal, it was stated that human 
PFOA exposure has been shown to be linked to foetal transfer resulting in immunosuppression 
and reduced birth weight of children, as well as metabolic disturbances (T3, cholesterol) and 
increased time to pregnancy in adults. Various epidemiological studies that had suggested 
associations between PFOA exposure and various effects (e.g. reduced birth weight, elevated 
cholesterol levels) were used to calculate both internal and external DNELs for the general 
population as well as highly exposed workers. With available LOAEL data, DNELs were calculated 
for the different effects based on both animal external intake data but also on human exposure 
biomarker data. The restriction proposal contained DNELbiomarker values calculated on the basis of 
reduced birth weight or increased cholesterol levels observed in human population studies. The 
lowest DNELbiomarker values, 0.3 ng/ml serum and 0.6 ng/ml serum for the general and worker 
population, respectively, were based on reduced birth weights. Increased cholesterol levels 
resulted in slightly higher DNELbiomarker values of 0.74 ng/mL and 1.47 ng/mL, for general population 
and workers, respectively. 
The risk characterisation suggested that the highest exposed among the general population is not 
protected towards the hazardous effects of PFOA. The RCRs for adults were 2-70 and for children 
even higher, 3-148. When evaluating these RCRs, the recent human data showing an impaired 
immune response associated to PFOA exposure were not taken into account, as these were not 
available at that time. These include the studies in the Faroese population by Grandjean and co-
workers who have suggested an association between PFAS (including PFOA) exposure and 
impaired immune response in children. When childhood vaccination responses were used as a 
clinically relevant outcome, PFAS concentrations in maternal pregnancy serum showed a strong 
negative correlation with vaccine antibody concentrations in children at 5 years of age. This 
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occurred at dose levels which could result even lower DNELs (and thus higher RCRs). As humans 
are exposed to several PFAS compounds, possible mixture effects should ideally also be taken 
into account in risk assessment if the same target organs and MoAs can be assumed.  
In general, the human studies resulted in lower DNELs than the rodent studies, suggesting that 
humans are more sensitive to the hazardous effects of fluorinated chemicals than rodents. Under 
physiological conditions PFOA is readily dissociated to the conjugate base perfluorooctanoate 
(PFO), which is the form actually measured in HBM. In the literature, however, it is referred to as 
PFOA. The use of HBM data has been invaluable in the risk assessment of PFOA due to the 
marked species differences in kinetics between animals and humans, bioaccumulative properties 
of PFOA and due to the availability of epidemiological human health and exposure data. 
ECHA RAC opinion on PFOA restriction proposal 
Following the restriction proposal described above, ECHA’s risk assessment committee discussed 
this and subsequently published their opinion (ECHA, 2015g). The RAC opinion was mainly based 
on PBT properties of PFOA, which were alone sufficient for restriction. However, PFOA internal 
DNELs were also derived based on animal and human studies. The RAC did not agree with some 
proposals in the restriction dossier submitted by Germany and Norway. RAC derived a 
DNELbiomarker of 800 ng/ml and 1600 ng/ml for the general population and the worker population, 
respectively, arguing that a DNEL cannot be reliably derived from human data (ECHA, 2015g). 
Especially, dose-response related to the reduced birth weight were considered unreliable since the 
dose-response was seen only in general population studies with PFOA serum levels <10 ng/mL, 
but not in studies among highly exposed populations (populations living nearby contaminated sites 
with serum levels >50 ng/mL and occupationally exposed populations). The reasons for this 
discrepancy were not discussed in RAC opinion but may include confounders like co-exposure to 
other PFAS compounds among general population and reduced plasma volume expansion and 
therefore reduced clearance of PFOA through glomerular filtration as described Annex XV 
Proposal for a Restriction –PFOA, PFOA salts and PFOA-related substances (ECHA, 2014c). 
German Human Biomonitoring Commission 
The German Human Biomonitoring Commission has published a reassessment of the HBM values 
of PFOS and PFOA in 2016 (UBA, 2016). The HBM I value represents the concentration of a 
substance in human biological material below which no risk for adverse health effects over life time 
is expected (HBM Commission 2014). The respective HBM I values are 2 ng PFOA/ml and 5 ng 
PFOS/ml blood plasma (HBM Commission 2016). The HBM Commission has decided to use the 
existing POD ranges of 1 to 10 ng/ml as a basis and selected 2 ng/ml comprising the HBM I value 
for PFOA, pointing to the consistency of results from animal and epidemiological studies.  
EFSA’s risk assessment of PFOA 
The current risk assessment by EFSA of PFOA from 2008 is based on data from animal 
experiments; more specifically the TDI is based on liver toxicity in rats and mice with a BMDL10 of 
0.3 mg/kg bw/day. This results in a TDI of 1.5 µg/kg bw/day. 
This TDI gives rise to an acceptable intake of 90 µg PFOA/day for a 60 kg person (eating 1 kg food 
per day). This value does not take sufficiently into account that PFOA accumulate in humans and 
the environment causing exposure to increase over time. Ideally the risk assessment should be 
based on body burdens, as it is done for e.g. dioxins and PCBs. 
In order to evaluate the contribution to human PFOA exposure from food contact materials, a study 
at DTU Food showed that migration from cake and popcorn packaging materials gave rise to a 
calculated human exposure that occupied 4-12% of the present TDI set by EFSA. In light of the 
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current high TDI that needs re-evaluation, this exposure from food contact materials is of concern. 
Currently EFSA is re-evaluating the PFOA risk assessment in the light of new data, especially 
human data that has appeared since 2008. 
Biomonitoring of residents exposed to PFOA –Dutch case study 
There are some populations in Europe such as the Ronneby population in Sweden and a 
population in the Netherlands, which have been exposed to high levels of PFOA due to the 
environmental contamination. In the Netherlands, the health effects of the persistent PFOA are 
currently under investigation. The trigger is the Chemours scandal, in which residents living in the 
vicinity of a Teflon factory in Dordrecht have been exposed for 25 years (1970-2012) to elevated 
concentrations of PFOA. In addition to measurements of PFOA in water and air, blood samples 
have been taken from 382 residents distributed over four exposure groups. The measured PFOA-
levels in blood (Van Poll et al., 2017)  for the highest exposed group (up to 750 m from the plant) 
were in the range of 1.3 (minimum) – 147 (maximum) ng/ml serum with a median of 10.2 ng/ml. In 
a control area levels were 0.9 – 14.1 ng/ml serum with a medium of 3.4 ng/ml. From the 382 
residents, 18 had a serum level of PFOA higher than 21 ng/ml, which is the maximum average 
European background level (ECHA, 2015h). The measured serum levels of PFOA appear to be 
similar to values calculated in 2016 using a computer model and support the risk assessment 
carried out. Depending on the exposure scenario, the levels calculated for the highest exposed 
groups were 80 -130 ng/ml serum (Zeilmaker et al., 2016). The health limit derived was 89 ng/ml 
serum. This limit value is based on liver toxicity in rats with a NOAEL of 0.06 mg/kg bw/day 
extrapolated to chronic human inhalation exposure using kinetic modelling that takes into account 
accumulation of PFOA. The human biomonitoring data therefore underscore the conclusion from 
2016 that the general population health limit value of PFOA was exceeded for long periods of time 
and may have caused adverse health impacts. The link to health effects will be made through 
literature research and additional interviews with residents with higher exposures leading to serum 
levels above 21 ng/ml. The results of this study will be published at the end of the year 2017. 
 Summary of different PFOA assessments 
Within the various regulatory communities discussions on the most sensitive health endpoints are 
still ongoing. Recently, Fletcher and Stayner, presented a BMDL01 (1% BMDL) of 2.8 ng/mL based 
on increased cholesterol levels, which was considered to represent the best characterised health 
effect in humans seen in a wide range of serum PFOA levels (Fletcher and Stayner, 2017). Results 
of the ongoing EFSA assessment are expected in autumn 2017.  
The ‘orders of magnitude’ difference (e.g. a factor of 400 between the RAC proposed DNEL of 800 
ng/ml and the German HBM-I of 2 ng/ml) highlights the need for alignment or at least 
communication of the various risk assessment bodies throughout Europe when it comes to hazard 
assessment, be it based on animal studies of human epidemiology and the subsequent derivation 
of a health based guidance value. Overall, however, human studies suggest that humans may be 
more sensitive to the hazardous effects of fluorinated chemicals than rodents. In addition, when 
taking into account the bioaccumulative properties of PFOA, human biomonitoring is the best way 
to assess the exposure to PFOA. 
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 Anilines 
 Use of biomonitoring in the authorisation of MOCA 
MOCA is an aniline derivative, which is used primarily as a curing agent in polyurethane 
production. It is a genotoxic carcinogen to which a threshold for carcinogenic effects cannot be 
assigned. In animal studies it has caused increased incidence of lung, liver, mammary gland and 
urinary bladder cancers. Because of its carcinogenic properties, it was added to Annex XIV of 
REACH and it is currently authorised under REACH. MOCA has a low volatility and it is easily 
absorbed via the skin. Therefore, human biomonitoring is very valuable tool for the assessment of 
exposure to it in occupational settings. In occupational studies in polyurethane industry, urinary 
MOCA levels has correlated best with the MOCA surface contamination, whereas air levels have 
been often low (Cocker et al., 2009; Keen et al., 2012). 
ECHA has performed a dose-response analysis for the carcinogenicity of MOCA and calculated 
cancer risk levels for different MOCA intakes (ECHA, 2015c). In its dose-response documentation 
ECHA also presents estimated cancer risks for different urinary MOCA levels measured as total 
urinary MOCA in the end of the work-shift in the end of the work week (ECHA, 2015c). Since 
urinary MOCA levels do not correlate with MOCA air concentrations, it is not possible to directly 
calculate urinary levels which correspond to occupational exposure to specific air levels. Neither 
there are any PBTK/PBPK models for MOCA. Therefore, in ECHA’s document an open one-
compartment model based approach was used to roughly estimate the daily doses corresponding 
to urinary MOCA level of 5 µmol/mol creatinine in the Friday afternoon (end of shift) sample 
(ECHA, 2015c). This was provided to the applicants of authorisation to facilitate the use of 
biomonitoring in the exposure assessment of MOCA in its industrial uses. General population is 
usually not exposed to MOCA, and the levels of MOCA and its metabolites in the urine of the non-
occupationally exposed population are below the detection limits. 
There is one application for authorisation for MOCA available at ECHA website (application by 
ReachLaw, 2016). It covers up to 89 sites in EU using MOCA as a curing agent in polyurethane 
production. Estimated number of exposed workers in EU is about 200. The authorisation has been 
applied for 12 years, but the commission decision or the ECHA committees (RAC and SEAC) 
recommendation on the application is not available yet. The applicant has used HBM data to 
assess the workers’ exposure to MOCA (Reachlaw, 2016). In addition, there are published studies, 
especially from UK, on the exposure to MOCA in polyurethane manufacturing (Cocker et al, 2009; 
Keen et al., 2012, Robert et al., 1999). These all show urinary MOCA levels in the manufacturing of 
polyurethane which are about 10 μmol/mol creatinine or below. Using RAC dose response, this 
can be calculated to correspond the excess cancer risk of 3.3 x 10-5. Besides HBM data, in the 
CSR the applicant has used modelling to assess inhalation and dermal exposure. Dermal 
exposures up to 13 -14.5 µg/kg bw were predicted by the model for two worker’s contributing 
scenarios resulting in highest exposure in manual polyurethane moulding process. These can be 
calculated to correspond to a daily intake of up to about 450-500 µg/day and urinary levels up to 
130-150 µmol/mol creatinine when assuming 50% bioavailability via dermal route (50% 
bioavailability via dermal route was assumed by RAC in its dose-response analysis. Thus, when 
comparing these values to available HBM data, it is evident that modelling of exposure results in a 
significant overestimation of exposure and risk. This example demonstrates how human 
biomonitoring can be used for more accurate exposure and risk assessment. Benefits of human 
biomonitoring in occupational exposure assessment include also that it takes into account also 
hand-to-mouth exposure, which cannot currently be assessed by any modelling tool. In this case, it 
is of particular relevance since MOCA has low volatility and can be present for a long period on 
workplaces surfaces facilitating this exposure route. 
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 Polybrominated diphenylethers (PBDEs) assessment group 
A good example on the use of HBM data under the mixtures framework is given in the publication 
by M.E. Meek et al. / Regulatory Toxicology and Pharmacology 60 (2011) S1–S14, (Annex A). This 
concerns PBDEs. In this case, conservative upper-bounding estimates of total intake of PBDEs 
were derived based on maximum levels in air, water, dust, food and human breast milk and 
standard intake values for six age groups within the Canadian population. These upper-bounding 
estimates of exposure were considered conservative, in that they were based on summed 
estimates for all congeners for which data were available and highest measured concentrations for 
many media. Comparison of the critical effect level (i.e. 0.8 mg/kg bw per day for neurobehavioural 
effects in mice following neonatal exposure) with the upper-bounding deterministic estimate of 
exposure for the intake of total PBDEs (2.6 μg/kg bw per day in breastfed infants) resulted in a 
margin of exposure of approximately 300. Margins based on available HBM data were 
approximately 10-fold less. These were estimated through back-calculation of intakes by first-order 
kinetic modelling of limited data on levels in blood of the general population and comparison of 
estimated body burden for the critical study in animals with that for breastfed infants. However, 
confidence in these estimates was considered to be less, owing to the considerable limitations of 
the relevant data on biological half-lives of PBDEs in humans and their seeming inconsistency with 
what would be expected based on relevant physical/chemical properties. The degree of 
conservatism in this margin is relevant to its interpretation. One critical aspect is the large inter-
individual variability in levels of PBDEs in breast milk within the general population. It should be 
noted that mean and median values for levels in breast milk were as much as 400- and 200-fold 
less, respectively, than the maximum values on which the estimates of exposure were based.  
In comparison, effect levels in chronic studies for the same congener were approximately 100 
times higher than that used in the margin of exposure. The margin of exposure does not, however, 
take into account the potential continuing increase in body burden of PBDEs (based on data for 
breast milk), should similar use patterns continue. Based on limited data, levels of PBDEs in 
human breast milk in Canada appear to be increasing with time (e.g. there was a 9-fold increase in 
mean concentration between 1992 and 2001). Prediction of trends in body burdens is precluded by 
the limited information on the toxicokinetics of PBDEs in humans and animals and transfer from 
human breast milk to infants, as well as the uncertainty in half-lives for removal processes for 
PBDEs in environmental media. 
On the basis of this example, it can be concluded that HBM supported by PBPK/PBTK modelling is 
a pivotal tool in the domain of mixture exposure (cumulative exposure). 
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6 Overall summary and conclusions 
In this report we have evaluated several international (WHO, UN FAO) and EU risk assessment 
schemes and the role of human biomonitoring in these schemes. Summary of the findings of this 
evaluation are presented in Table 7.  
Table 7: International and EU risk assessment schemes 
Risk 
Assessment 
Scheme 
Biomonito
ring 
recognise
d as an 
exposure 
assessme
nt tool 
Biomarkers 
of effect 
recognised 
as possible 
tools for e.g. 
hazard 
characterisa
tion  
Specific 
guidance 
available for 
the use of 
biomonitori
ng in risk 
assessment  
Examples on the use of HBM 
exists. If these include 
HBM4EU priority chemicals, 
these are given in brackets 
Remarks 
WHO risk 
assessment 
scheme 
yes yes yes  yes 
(toxic metals e.g. Hg/MethyltHg, Cd, 
Cr), toluene, nitrobenzene, etc.) 
GEMS; 
IPCS/INCHEM  
 
FAO risk 
assessment 
scheme 
yes yes no no  
REACH yes 
(occupationa
l /consumer 
/humans-via-
the-
environment 
exposure 
assessment) 
no  +/-* yes, HBM data were used for the 
needs of authorisation & restriction 
dossier 
(phthalates, BPA, MOCA, 
chromates, MDA) 
*REACH guidance 
R8 mentions the 
possibility to 
derive DNELs 
based on 
biomarker levels 
EFSA  Yes Yes Yes Yes (cadmium and lead) Guideline for risk 
assessment of 
contaminants in 
food and feed 
EFSA review Yes Yes No Yes (Metals; PCBs; cotinine; 
mycotoxins; perchlorate; 
nitrosamine; alkaloids; dioxins; 
phthalates; PAHs; furans; 
fluorocarbons; organochlorines; 
phenols; PFCs; PBDEs; 
organophosphates; pyrethroids; 
chlorinated phenols; acrylamide; 
carbamates) 
WHO risk 
assessment 
guidance is 
followed 
EFSA  review Yes Yes No Yes (PCBs, PBDEs, PFASs, PAHs, 
Parabens, Perchlorate, BPA,  
Phytoestrogen, VOCs) 
Document 
focused on 
vulnerable groups 
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Risk 
Assessment 
Scheme 
Biomonito
ring 
recognise
d as an 
exposure 
assessme
nt tool 
Biomarkers 
of effect 
recognised 
as possible 
tools for e.g. 
hazard 
characterisa
tion  
Specific 
guidance 
available for 
the use of 
biomonitori
ng in risk 
assessment  
Examples on the use of HBM 
exists. If these include 
HBM4EU priority chemicals, 
these are given in brackets 
Remarks 
EU Pesticides yes yes no HBM has been used for monitoring 
worker exposure. Most studied 
pesticides: 
Herbicides (in order): 2,4-D > 
atrazine > metolochlor = MCPA > 
alachlor = glyphosate. Insecticides 
(in order) were: chlorpyrifos > 
permethrin > cypermethrin = 
deltamethrin > malathion, 
Fungicides were: captan > 
mancozeb > folpet 
Data from: Human 
biomonitoring data 
collection from 
occupational 
exposure to 
pesticides –EFSA 
supporting 
publication 
2017:EN-1185. 
207 pp. 
EU Biocides yes no  no no  
EU Cosmetics no no no yes HBM data 
considered as 
support and 
complementary 
information only 
EU OSH yes no (legislation, 
however, 
SCOEL 
methodology 
recognises this 
possibility) 
no only B-Pb taken into the legislation, 
however, SCOEL recommendations 
available for several HBM4EU 
priority chemicals, see table 6 
Biomonitoring 
considered as part 
of health 
surveillance. 
Under CAD or 
CMD no BLVs 
given except for 
P-Pb) 
WHO HIA 
scheme 
Yes ? No Yes, lead, dioxins, EDCs in general Current status: 
Dose-response 
relationships 
mainly based on 
external exposure 
 
As can be seen from table 7, in most risk assessment schemes some reference to human 
biomonitoring has been made. Human biomonitoring is generally considered as a useful tool, 
which can be used as a 3rd tier method for the refinement of exposure assessment. Only few risk 
assessment schemes recognise, however, the possibilities of the effect markers in the hazard and 
dose-response analysis possibly due to uncertainties associated with HBM dosimetry for the 
setting the relevant dose descriptor. In addition, lack of guidance and lack of knowledge on the 
meaning of different effect markers may have an impact on this. 
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Although examples of the use of HBM data in the risk assessment can be found from almost all 
regulatory areas, the guidance on the use of HBM in risk assessment is generally either limited or 
missing. This was noted both in the evaluation of the risk assessment guidance and in the survey 
made to risk assessors. In food safety area, EFSA has, however, made recently good work to 
evaluate the use of HBM data in food safety and pesticide assessment. Additionally, guidance on 
the new possibilities to use human biomonitoring data could be useful; as the reduction in animal 
testing (3Rs) is reality and experimental information on e.g. toxicokinetics may be in many cases 
lacking, the existing HBM data could be integrated with data using non-animal methods (in vitro, in 
silico and HTP screening) in combination with computational modelling (PBTK) to generate more 
reliable information on toxicokinetics and to provide linkages between AOPs and human internal 
levels. 
It seems that in some regulatory areas (e.g. REACH) the data requirements for registration do not 
in practise support the use of human biomonitoring although in principle human biomonitoring is 
given as an option for exposure assessment. This is mainly because there is no incentive to 
understand the relationship between internal exposure and health effects, and also toxicokinetics 
data, which is essential for the use of HBM data, does not belong to the basic data requirements 
under REACH. In addition, IUCLID database, meant for the registration of chemicals does not 
currently include a place for biomarker based DNELs. 
In some regulative areas (pesticides, biocides) use of volunteer studies in the approval of new 
substances is not allowed. This may also limit the use of HBM data in those areas.  
Under EU OSH legislation human biomonitoring is considered as health surveillance, and no clear 
distinction between exposure assessment using human biomonitoring as part of workplace risk 
assessment and management, and health surveillance (or assessment of individual health risks) of 
workers is made. The results of the human biomonitoring surveys are not always communicated to 
the employers due to the privacy concerns (even as summarised results of the group of workers), 
which limits their use in the risk assessment and management at workplace. Health based 
limit/guidance values (or biological equivalents) are considered important for the use of HBM not 
only in OSH field but also in other risk assessment fields. In OSH, also regulations seem to be 
important drivers to conduct human biomonitoring. Thus, following main conclusions can be made 
on the basis of the survey and the evaluation of risk assessment schemes: 
 There is a general need for 1) having a reliable human biomonitoring methods using a 
specific marker for the substance of concern and 2) better guidance for the use of human 
biomonitoring in risk assessment under different risk assessment schemes. Examples of 
the successful use of human biomonitoring in risk assessment should be gathered and 
used in the development of such a guidance.  
 Scientifically sound health based limit/guidance values (such as derived via the biological 
equivalents approach), preferably with at least some regulatory status are essential for 
chemical risk assessors to use measured HBM data in the risk assessment process. These 
should be developed at EU level. The lack or paucity of toxicokinetic data may, however, 
hamper the derivation of HBGVs. Fortunately, PBTK/PBPK modelling may be helpful9. 
 In OSH, legal enforcement seems essential – therefore, there is a need for inclusion of 
more BLVs in CAD/CMD. There is also a need for distinction between worker’s health 
surveillance and human biomonitoring as part of workplace exposure and risk assessment 
and guidance for the use and communication of HBM data. 
                                               
9 The publication of Boogard et al. (2011) is providing pragmatic guidance on how HBM can be applied in risk characterisation under 
REACH using DNELs based on the concept of deriving BE. It concludes that coupling HBM data with a dose-response assessment 
based on internal and/or absorbed dose via use of BE provides a very powerful and scientifically robust approach to conduct RA. 
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In addition to the evaluation of the different risk assessment schemes we have presented 5 
examples on the use of HBM in risk assessment. These include risk assessments of four 
phthalates (DEHP, BBP, DBP, DiBP), BPA, PFOA, MOCA and flame retardants. First three 
examples are based on the risk assessments under REACH restriction process, MOCA case is 
based on the authorisation application made for its use under REACH and flame retardants 
example is based on the publication by Meek et al (2011), which represents the use of human 
biomonitoring under WHO mixtures framework. These risk assessment cases describe the 
advantages of the HBM in the risk assessment; especially related to the refinement of exposure 
assessment. In addition, like in the case of occupational BPA exposure of cashiers, it can be used 
to support modelling data, giving a stronger basis for the assessment. In the PFOA case, human 
epidemiological studies based on the exposure biomonitoring suggest that humans may be more 
sensitive to the hazardous effects of fluorinated chemicals than rodents. In addition, it also shows 
challenges related to the interpretation of human epidemiological data, which have, by this far, 
resulted in the highly variable conclusions on the dose-responses of the hazards of PFOA to 
humans. In many of these cases there are still room for the refinement of the risk assessment; in 
PFOA case the need is obvious but also e.g. in the case of BPA the HBM based risk assessment 
included some uncertainties related for example on the fraction of free BPA available for systemic 
distribution after dermal exposure. In the case of phthalates, further follow-up of phthalate levels in 
general population will bring valuable information on the effectiveness of phthalate restriction. 
Further assessment could take into account also the levels of other, less regulated phthalates.  
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7 Proposals/recommendations for the better inclusion of HBM 
in risk assessment and health impact assessment 
For the better inclusion of HBM in risk assessment and HIA, the first priority is to develop 
harmonised guidance for the various phases of HBM (recruiting, sampling, analysis, quality 
assurance, data management, data assessment, communication, follow-up strategy) in order to 
ensure the quality of the data collected. In addition, there is a need to: 
 Create awareness on the capabilities of HBM and start discussions with regulators at EU 
and national level on better anchoring of HBM as tool in the various horizontal and vertical 
EU legislative risk assessment frameworks. This is critical to increase the frequency of use 
of the HBM tool as well as to create a level playing field for industry in Europe.  
 It is important to build further on important existing knowledge. Thus groups of chemicals 
where the existing knowledge might be sufficient to derive robust health based 
biomonitoring limit/guidance levels or biological equivalents, should be considered first (this 
is already on-going under HBM4EU). Successful examples on the use of HBM should be 
created and collected (also on-going activity under HBM4EU) and used as a basis for the 
guidance on the use of HBM in RA/HIA. 
 The existing HBM data should be integrated with data to be delivered using non-animal 
testing methods (in vitro, in silico and HTP screening) in combination with computational 
modelling (PBTK) to generate more reliable information on toxicokinetic and to provide 
linkages between AOPs and human internal levels. Well-designed HBM studies should be 
considered for this development with selection of priority groups of chemicals (e.g. CMR 
and EDCs).  
 HBM has to be incorporated almost by default in European studies addressing exposure to 
mixtures, since HMB is probably the only way to obtain realistic exposure data regarding 
mixtures and aggregate exposure to chemicals from different sources. The collection of 
human biomonitoring data for pesticide workers should be considered to be added as 
routine component of existing occupational health surveillance programs in Europe. 
 HBM data should be used to validate integrated and aggregated external and internal 
exposure models. At the same time, these iterative efforts that will include adjustments to 
parameter settings (input data on exposure factors and time-activity patterns) will allow 
identification of critical exposure parameters.  
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Annex A 
 
 
 
Figure A1: Scheme for assessment of health and environmental impacts. Figure 18 from (ECHA, 
2008b) 
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Figure A2: Integrated environmental HIA in relation to other forms of risk and impact assessment 
(Briggs, 2008)  
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Annex B 
Questionnaire on human biomonitoring (HBM) for risk assessment 
purposes 
Human Biomonitoring (HBM) is an important tool to survey the body burden of humans resulting 
from exposure to chemicals via different routes (lung, skin, digestive tract). Inclusion of HBM data 
could improve human health risk assessment of general people (exposure via air, drinking water 
and food) as well as workers, by providing more accurate data on exposures. In addition, by using 
HBM it could be possible to make direct linkage between internal exposure and AOPs (adverse 
outcome pathways) resulting in adverse health effects. Especially if the pollutant has a cumulative 
effect, and e.g. if the working conditions (personal protection equipment, inter-individual differences 
in respiratory ventilation, etc.) determine large differences in internal dose between individuals that 
are not taken into account by atmospheric metrology biomonitoring has proven its usefulness. 
EU-funded project, HBM4EU, aims to develop new European wide biomonitoring based exposure 
data and exposure-health effect relationships based on internal exposure biomarkers and effect 
biomarkers for use in the risk assessment of chemicals. The ultimate goal is to improve human risk 
assessment of priority chemicals and mixtures by more efficient application of HBM. In order to 
achieve this goal, the current risk assessment practises in different countries and the current use of 
human biomonitoring in risk assessment of chemicals are evaluated. Therefore, we invite risk 
assessors, working under different regulatory contexts, to answer the short questionnaire on the 
use of HBM in risk assessment of chemicals. 
You can exit the questionnaire at any time and return later to complete or revise the answers. To 
do so, please choose "Save & Continue later” and carefully record the address of the return link. 
After the last page you'll get to the summary page where you can review your answers. To submit 
the questionnaire click “Finish” at the bottom of the summary page. 
Responses will be treated with confidentiality and sensitivity by the researchers. Gathered data will 
only be used for the purpose of research within HBM4EU and will be presented in an anonymised 
form. 
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1. 2. Under which regulatory frameworks are you working? Please select one or more 
options. 
Number of respondents: 71, selected answers: 137 
 
 N Percent 
REACH 30 42,25% 
Food 22 30,99% 
Occupational health and safety 28 39,44% 
Pharmaceuticals 4 5,63% 
Cosmetics 13 18,31% 
Plant protection products 8 11,27% 
Biocides 11 15,49% 
Circular economy and material cycles 3 4,23% 
Other, please specify 18 25,35% 
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Answers given into free text field 
Option names Text 
Other, please specify researcher 
Other, please specify Chemical safety 
Other, please specify Food Contact Materials 
Other, please specify CLP 
Other, please specify Specific regulations for pesticides in the public health sector 
Other, please specify Stockholm convention on POPs 
Other, please specify consumer products 
Other, please specify Environmental Health 
Other, please specify Contaminants in food 
Other, please specify BREFs 
Other, please specify POPs, Consumer and construction products, indoor air, 
Other, please specify Toys, Clothing, and other consumer products 
Other, please specify Nanotechnology 
Other, please specify Pharmaceutical veterinary medicines 
Other, please specify Water, air 
Other, please specify CLP 
Other, please specify CLP 
Other, please specify Public health 
 
2. 2.1. If you are working only in the field of occupational health and safety, select "Yes" to 
move to the questions addressing only those aspects. If your work is divided to 
other fields as well, select "No" to continue to the questions on human 
biomonitoring on general population. 
Number of respondents: 28 
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 N Percent 
Yes, I work only in the field of occupational health and safety 16 57,14% 
No, I work also in other fields 12 42,86% 
 
3. 3A. Considering the regulatory field you are working, is human biomonitoring regularly 
applied in your country? 
Number of respondents: 55 
 
 
 N Percent 
Yes 15 27,27% 
No 21 38,18% 
Only in limited extent, please explain below 19 34,55% 
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4. 4A. Is there any guidance (regulatory, institutional) for the use of human biomonitoring 
data for risk assessment in your country? 
Number of respondents: 55 
 
 
 N Percent 
Yes 10 18,18% 
No 35 63,64% 
Do not know 10 18,18% 
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5. 5A. If applicable in your country, what are the main drivers to start human 
biomonitoring campaign in general population? Select at maximum three main 
drivers. 
Number of respondents: 50, selected answers: 128 
 
 N Percent 
Confirm exposure to a specific substance 27 54% 
Assess the magnitude of internal exposure to a substance 26 52% 
Health Surveillance 16 32% 
To support risk assessment and define priorities for intervention 25 50% 
To support risk management measures 12 24% 
To confirm data from environmental monitoring/modelling campaigns 12 24% 
Other, please specify 0 0% 
Do not know 2 4% 
Biomonitoring is not usually performed in my country 8 16% 
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6. 6A. In your country, is there any specific guidance for the technical and organisational 
application of HBM? 
Number of respondents: 55 
 
 
 N Percent 
Yes 10 18,18% 
No 23 41,82% 
Do not know 22 40% 
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7. 7A. In your opinion, how could human biomonitoring best contribute to risk 
assessment/management and possibly, in a few years from now, with new 
developments? Select three most important aspects 
Number of respondents: 55, selected answers: 157 
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 N Percent 
Providing realistic exposure data 33 60% 
Historical/retrospective exposure data 2 3,64% 
Combining different exposure routes –> estimate total internal exposure 26 47,27% 
Integrate single chemical exposure due to the presence in various products or 
products and workplace atmosphere (aggregate exposure) 
8 14,55% 
Assess combined exposure such as in Common Assessment Groups (CAG) as used 
for pesticides (combined exposure assessment), e.g. by measuring a similar or 
identical metabolite 
6 10,91% 
Prioritisation of risk management / policy / intervention 23 41,82% 
Assessing temporal exposure trends 7 12,73% 
Assessing effectiveness of policy/risk management actions 14 25,45% 
Characterising geographical patterns of exposure or effect 6 10,91% 
Comparing different population subgroups and identifying vulnerable subpopulations 20 36,36% 
Using more biological effect markers in biomonitoring to detect early effects 7 12,73% 
Other, please describe: 5 9,09% 
 
Answers given into free text field 
Option names Text 
Other, please describe: Comparision of HBM data with health based guidance values 
Other, please describe: Surveillance of new emerging contaminants of concern 
Other, please describe: Support epidemilogical research 
Other, please describe: 
These are all very relevant aspects of HBM and all of them would be 
beneficial. 
Other, please describe: 
Integrating routes and sources, but with the remark that source contribution 
(often needed for policy makers) is very difficult! 
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8. 8A. In your country, do you use or have you used DNA or protein adducts as a marker 
of exposure in the risk assessment? 
Number of respondents: 55 
 
 
 N Percent 
Yes 11 20% 
No 21 38,18% 
Do not know 23 41,82% 
 
9. 9A. In your country, do you use or have you used biomarkers of effect (including e.g. 
“omics”-based markers) in the risk assessment? 
Number of respondents: 55 
 
 N Percent 
Yes 6 10,91% 
No 24 43,64% 
Do not know 25 45,45% 
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10.10A. What are your criteria for using human biomonitoring data in risk assessment? 
Please tick all relevant options. 
Number of respondents: 51, selected answers: 185 
 
 
 N Percent 
Existence of validated method for biomonitoring 38 74,51% 
Existence of health based biological limit/guidance values* (BLVs/BGVs) 28 54,9% 
If it is possible to calculate biomonitoring equivalents** for health based limit values 
(e.g. for ADIs/TDIs) 
20 39,22% 
Existence of biological reference (background/normal) values*** 24 47,06% 
Sufficient population size 25 49,02% 
Human biomonitoring level can be related to the exposure source 27 52,94% 
Biomonitoring level can be directly related to the health effects 22 43,14% 
Other, please specify below 1 1,96% 
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11.11A. According to your experience, how often can your criteria for using human 
biomonitoring data in risk assessment be fulfilled? 
Number of respondents: 49 
 
 
 N Percent 
Always 1 2,04% 
Very often 2 4,08% 
Often 11 22,45% 
Sometimes 19 38,78% 
Rarely 16 32,65% 
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12.12A. In your country, are HBM results of the general population usually compared to 
biological limit values (BLVs)/biological guidance values (BGVs) or reference 
values set for general population? 
Number of respondents: 48 
 
 
 N Percent 
Yes, to health based BLVs or BGVs 7 14,58% 
Yes, to reference values or population distribution based BGVs 2 4,17% 
Yes, both 11 22,92% 
None of these 28 58,33% 
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13.12A.1. Please specify the substances for which there is a BLV or a BGV in your country. 
You can also provide a link to the list of BLVs or attach a list as an attachment. 
Number of respondents: 13 
Responses 
1) German HBMI values 
2) Biomonitoringequivalents (summit toxicology) derived by different international organisations (EFSA, 
USEPA, etc.) 
Please consult Tiina Santonen@ttl.fi 
See SCOEL list 
In case of need, reference and HBM values are taken from the German Umweltbundesamt; see the list 
there 
Please address to the Austrian Umwelbundesamt 
We refer to HBM values of the German HBM Commission and other health based HBM values; for 
Occupational Risk assessment some BAT values are listed in the respective Regulation 
Use of internationally derives limit/guidance values 
www.rivm.nl/bibliotheek/rapporten/609300023.pdf 
See appendix 7 for the Biological Limit Values 
For contaminants in food, biomonitoring levels are compared with the levels used as basis for setting TDIs 
at EFSA. For instance: 
-  The blood Pb concentration associated with 2% increase in blood pressure at population level or the 
one Associated with a 1% decreased IQ in children or with increased risk of kidney disease in the adult 
population. 
- The urinary Cd level considered safe by EFSA in relation to kidney disease 
- The blood Hg concentration not associated with adverse cognitive effects in children 
https://www.ciop.pl 
Toluène 
Styrène 
DEHP 
acrylamide 
BBP 
DBP 
hexavalent chromium and his compounds 
2-butoxyéthanol & acetate 
BLV (D.Lgs 106/09): Pb blood 60 µg/100 ml (40 µg/100 ml women<45 years) 
RVs from various sources: 
A. Alimonti, B. Bocca, D. Mattei, A. Pino. Programme for Biomonitoring the Italian Population Exposure 
(PROBE): Internal Dose of Metals. Istituto superiore di sanità. Rapporti Istisan 11/9 (2011) 
SIVR. Terza lista dei valori di riferimento per elementi, composti organici e loro metaboliti. Edizione 2011. 
Società Italiana Valori di Riferimento, 2011 
Aprea C., Catenacci G. Valori di riferimento degli Antiparassitari. G Ital Med Lav Erg. 2003, 25(1):37-60 
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14. 12A.2. What is the legal status of these values? 
Number of respondents: 14, selected answers: 19 
 
 
 N Percent 
They are binding limits given by the law. Additional information (optional): 5 35,71% 
They are indicative limit values given by authorities. Additional information (optional): 7 50% 
They are recommendations of the laboratory/research institute. Additional information 
(optional): 
6 42,86% 
Other, please specify 1 7,14% 
 
Answers given into free text field 
Option names Text 
They are binding limits given by the law. 
Additional information (optional): 
This is true for occupational limit values. They do not directly 
apply to environmental exposures, but can be used for 
comparison 
They are binding limits given by the law. 
Additional information (optional): 
https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bun
desnormen&amp;Gesetzesnummer=10009034 
They are binding limits given by the law. 
Additional information (optional): 
Only for lead in blood 
They are binding limits given by the law. 
Additional information (optional): 
only for blood lead 
They are binding limits given by the law. 
Additional information (optional): 
D.Lgs 106/09 
Other, please specify Not aware 
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Option names Text 
They are recommendations of the 
laboratory/research institute. Additional 
information (optional): 
Yes, in Biotox a database produce by INRS. 
http://www.inrs.fr/publications/bdd/biotox.html 
They are recommendations of the 
laboratory/research institute. Additional 
information (optional): 
A. Alimonti, B. Bocca, D. Mattei, A. Pino. Programme for 
Biomonitoring the Italian Population Exposure (PROBE): 
Internal Dose of Metals. Istituto superiore di sanità (2011) 
They are indicative limit values given by 
authorities. Additional information 
(optional): 
German HBM values widely accepted in Austria 
They are indicative limit values given by 
authorities. Additional information 
(optional): 
SIVR 
 
15. 13A. For the substances for which no BLV or BGV exists, what references do you use 
to interpret data (e.g. BLV or BGV from other countries)? 
Number of respondents: 33 
Responses 
Comparison references values other countries 
Reference values from other countries 
No experience. 
We do not have much experience of using HBM data under REACH. DNELs and DMELs are used in 
REACH. 
We use international results 
Do not know (POPs?) 
Calculate biomonitoring equivalents for health based limit values 
All available data can in principle be used case by case. I am not aware of any "official" Swedish 
BLV/BGVs for the general population 
Exposure reference values (e.g. for food health based guidance values),  
Clinical reference values (i.e. GFR) 
BLV or BGV from other countries, or described in the literature. 
Non 
See answer to 12A 
BLV or BGV from other countries 
Levels at which effects were reported in epidemiological and/or toxicological studies. Reference values, 
expert opinion 
Probably such values would be used from other countries if available. 
HBM is rarely used in the general population. Only after incidents (eg PFOA - Du Pont) 
In that case RIVM derived a reference value. 
Rarely BE values from other countries 
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Responses 
HBM values of the German HBM-Commission, 
Values derived by ECHA, EFSA, WHO, ATSDR, Health Canada and others 
ACGIH, BAT, WHO, CDC, NAHES 
Question 12A should be answered by the Federal Environmental Agency (UBA). HBM data (e.g., urinary 
concentrations of metabolites of phthalates and BPA) can be used for back-calculating internal exposure, 
which in turn can be compared to TDI values. 
Use of internationally derives limit/guidance values 
Measurements in control populations 
Yes, or back calculate (if data allow) to (external) exposure estimates 
We don´t have experience of using HBM under REACH and Biocides 
BLV or BGV from other countries 
Literature data about dose-response 
I do not know. 
In France, INRS has a website (Biotox) in which reference values from other countries or institutions are 
listed (e.g. SCOEL, ACGIH, DFG, FIOH etc.) 
BLV or BGV from other countries 
No experience. 
RVs from Other Countries: 
C. Schulz, M. Wilhelm, U. Heudorf, M. Kolossa-Gehring. Update of the reference and HBM values derived 
by the German Human Biomonitoring Commission. Int. J. Hyg. Environ. Health, 215 (2011), pp. 26-35 
CDC (Centers for Disease Control and Prevention). National Report on Human Exposure to 
Environmental Chemicals. Department of Health and Human Services Atlanta, GA (2001) 
U. Ewers, C. Krause, C. Schulz, M. Wilhelm. Reference values and human biological monitoring values for 
environmental toxins. Int. Arch. Occup. Environ. Health, 72 (1999), pp. 255-260 
D. Haines, G. Saravanabhavan, K. Werry, C. Khoury. An overview of human biomonitoring of 
environmental chemicals in the Canadian Health Measures Survey: 2007 to 2019. Int. J. Hyg. Environ. 
Health, 220 (2017), pp. 13-28. 
A. Batáriová, V. Spěváčková, B. Beneš, M. Čejchanová, J. Šmíd, M. Černá. Blood and urine levels of Pb, 
Cd and Hg in the general population of the Czech Republic and proposed reference values. Int. J. Hyg. 
Environ. Health, 209 (2006), pp. 359-366. 
C. Freire, R.J. Koifman, D. Fujimoto, F. de Oliveira Souza Vanessa Cristina Barbosa, S. Koifman. 
Reference values of cadmium, arsenic and manganese in blood and factors associated with exposure 
levels among adult population of Rio Branco, Acre, Brazil. Chemosphere, 128 (2015), pp. 70-78. 
Schoeters G, Den Hond E, Colles A, Loots I, Morrens B, Bruckers L et al. (2012). The Flemish 
Environment and Health Study (FLEHS) – Second Survey (2007–2011): Establishing Reference Values 
for Biomarkers of Exposure in the Flemish Population. In: Knudsen E, Merlo DF, editors. Biomarkers and 
human biomonitoring. Volume 1. London: Royal Society of Chemistry, 135–165 (Issues in Toxicology, 
No.1). 
Fréry N, Vandentorren S, Etchevers A, Fillol C (2012). Highlights of recent studies and future plans for the 
French human biomonitoring (HBM) programme. Int J Hyg Environ Health, 215(2):127–32. 
Castaño A, Sánchez-Rodríguez JE, Cañas A, Esteban M, Navarro C, Rodríguez-García AC et al. (2012). 
Mercury, lead and cadmium levels in the urine of 170 Spanish adults: a pilot human biomonitoring study. 
Int J Hygiene Environ Health, 215(2):191–5. 
Snoj Tratnik J, Mazej D, Horvat M (2012). Human biomonitoirng studies in Slovenia – toxic metals, arsenic 
and essential elements. In: Human Biomonitoring (HBM) – Linking Environment to Health and Supporting 
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Responses 
Policy. Proceedings of the Conference, Larnaca, Cyprus, 22–25 October 2012. Nicosia: Ministry of Health, 
88. 
Smolders R, Den Hond E, Koppen G, Govarts E, Willems H, Casteleyn L et al. (2014). Interpreting 
biomarker data from the COPHES/DEMOCOPHES twin projects: Using external exposure data to 
understand biomarker differences among countries. Environ Res. doi: 10.1016/j.envres.2014.08.016 
[Epub ahead of print]. 
Wookhee Choi, Suejin Kim, Yong-Wook Baek, Kyungho Choi, Keejae Lee, Sungkyoon Kim, Seung Do Yu, 
Kyunghee Choi. Exposure to environmental chemicals among Korean adults-updatesfrom the second 
Korean National Environmental Health Survey (2012–2014). International Journal of Hygiene and 
Environmental Health 220 (2017) 29–35 
Biolomonitoring equivalents (BEs): 
Cd in urine (Hays et al., 2008); As inorganic in urine (Hays et al., 2010) 
No experience 
 
16. 14A. Is there work going on to elaborate health based limit values for general population 
in your country? 
Number of respondents: 53 
 
 
 N Percent 
Yes 8 15,09% 
No 11 20,76% 
Do not know 34 64,15% 
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17. 15A. What are the important obstacles you face when applying biomonitoring data in 
the risk assessment of general population? Please fill in matrix for the chemicals 
in general and for the following priority compounds. Notice that the table needs to 
be scrolled to the right to see the rest of the columns! 
Number of respondents: 39, selected answers: 506 
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18. 16A. In case it is possible to perform a health impact assessment based on HBM data, 
do you think this could be of additional value to assess certain policy goals 
(prospective and retrospective)? If yes, can you give an example? 
Number of respondents: 34 
Responses 
Yes, 
it's more convincing for policymakers. 
e.g. lead reduction in blood and avoidance of IQ loss in children 
- 
Yes, it is of additional value to assess certain policy goals 
Yes.  
We are using HBM data to monitor exposure of the general population to organophosphate pesticides, 
following a regulatory intervention. 
Evidence of exposure of certain chemicals 
HBM can be used to prioritise management of chemicals, if it is posible to rank the chemicals according to 
the risk. 
Yes 
-It can help for risk assessment, to identify emerging health concern and to protect vulnerable population. 
-To support regulatory measures (e.g. restriction) and assess their effectiveness 
-To assess application for authorisation 
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Responses 
-Identification of bioaccumulative substances 
Yes, in order to prioritise policy actions (e.g. DALYs determination regarding toxic compounds) 
Yes. mainly because the results would possibly be less speculative. It might also be reassuring if no or low 
exposures can be confirmed by HBM 
At this moment it is difficult to assess the risk for example acrylamide. Biomonitoring could be a way 
forward to assess the current and furture (after certain policy options) risk. HBM data could be of 
additional value to assess policy goals. 
Validation of dietary exposure assessement.  
Corrolation between HBM data and health effects. 
Yes. An important example of using HBM data in Brazil would be to access the real health protection 
impact provided by recent regulations imposed for mycotoxins in foods. 
Good example may be phthalates, upon their risk assessment are already based numerous legal acts, 
e.g. in REACH, in cosmetics, food contact materials 
Yes, we have applied this in the case of accidental exposure of a village to arsenic in drinking water. 
I do not understand the question. HBM measures exposure. It does not directly inform about health 
impact. It might help establishing a causal association between exposure and effect in a scientific study 
though. But how is it applied in impact assessment? HBM can inform about the success of policy 
measures (e.g. documenting downward trends in exposure) 
Yes, e.g. like it has been done for the lates phthalates restriction proposal prepared by ECHA and 
Denmark 
Yes. 
The main problem in epidemiology is exposure assessment. When a clear dose-respponse relationship 
between internal exposure and a health effect is found, measures to reduce the exposure can be taken, 
and incorporated in prospective policy goals. 
Yes 
at European Level (e.g. phthalate restricition based on HBM exposure data and risk assessment as well 
as calculating the magnitude of adverse effects and their costs) at International Level (UNEP: human 
biomonitoring data are an essential part of the risk profiles which are basis for listing substances under the 
convention. 
In Austria: reduction of residue Limits of HCB in food due to high Body burdens in a Population living in a 
contaminated area 
Lead regulatory environment - lower values over years due to regulations and changed practices 
Phthalates 
HBM can show internal concentrations. Useful for validation of exposure models and better estimation of 
intake routs if these models are linked to the HBM values 
Yes, but only dependent on the policy question, so only when relevant. 
Possibly 
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Responses 
Yes, health impact assessment based on HBM data is of additional value to assess certain policy goals. 
Example: phthalates 
Yes, policy goal should be to prevent exposure exceeding safe levels 
No 
I think HBM data could be used to perform a health impact assessment. 
Yes, lead free fuels 
Yes, I think this could be of additional value to assess our certain policy goals. It could help to prioritise 
policy goals as well as it allow to estimate current situation for the chemicals in general and/or for the 
certain priority compounds like phthalates or heavy metals in the different matrices (blood, urine etc.) 
YES 
We used data on lead level among children in certain polluted area (Mezica) as an indicator of efficiency 
of the measures 
Yes 
Example: 
 
A PFAS water contamination occurred in Veneto (Italy), and local policy makers undertaken a series of 
measures (e.g. carbon filters on the water supply system) to limit exposure of people residing in the areas 
interested by contamination. In order to assess the extent of the human exposure they also asked ISS to 
perform a HBM study that evidenced high serum PFAS concentrations in exposed subjects. As a 
consequence of HBM results health protection measures were added to actions to limit exposure, in 
particular a special health surveillance plan for overexposed subjects. 
yes 
Of course. By measuring the concentration of chemicals in body, biomonitoring allows to define exposure 
of chemicals and this data can be directly linked to epidemiological surveys, in order to estimate exposure-
response relationships and provide valuable information on potential health risks. 
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19. 17A. How do you communicate biomonitoring data in case of general population? Tick 
all options that apply 
Number of respondents: 41, selected answers: 69 
 
 
 N Percent 
Communicate to the person tested 19 46,34% 
Communicate to the health care 11 26,83% 
National Authorities in the scope of Health Programs 22 53,66% 
Other, please specify below 9 21,95% 
Not communicated 8 19,51% 
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20. 3B. Is human biomonitoring regularly applied in your country in occupational safety 
and health? 
Number of respondents: 27 
 
 
 N Percent 
Yes 15 55,56% 
No 3 11,11% 
Only in limited extent, please explain below 9 33,33% 
 
21. 4B. Is there any guidance (regulatory, institutional) for the use of human biomonitoring 
in the risk assessment at workplaces in your country? 
Number of respondents: 26 
 
 
 N Percent 
Yes 19 73,08% 
No 3 11,54% 
Do not know 4 15,38% 
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22. 5B. If applicable in your country, what are the main drivers to perform biomonitoring at 
occupational settings? Select at maximum three main drivers 
Number of respondents: 27, selected answers: 80 
 
 
 N Percent 
Confirm exposure to a specific substance 13 48,15% 
Assess the magnitude of internal exposure to a substance 14 51,85% 
Health Surveillance performed by occupational health care 18 66,67% 
To support risk assessment and define priorities for intervention 6 22,22% 
To support risk management measures 7 25,93% 
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 N Percent 
To confirm data from air monitoring/modelling 1 3,7% 
Regulations (e.g. B-Pb measurements required by law) 18 66,67% 
Other, please specify 0 0% 
Do not know 1 3,7% 
Biomonitoring is not usually performed in my country 2 7,41% 
 
23. 6B. If one of the main drivers to perform biomonitoring at workplaces is health 
surveillance made by occupational health care, are the biomonitoring data available 
for use in exposure assessment and management at the workplace? 
Number of respondents: 24 
 
 
 N Percent 
Yes 9 37,5% 
No, please explain why 5 20,83% 
Varies, please explain 7 29,17% 
Do not know 3 12,5% 
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24. 7B. In your country, is there guidance for the application of human biomonitoring in 
workplaces/occupational health care? 
Number of respondents: 26 
 
 
 N Percent 
Yes 20 76,92% 
No 3 11,54% 
Do not know 3 11,54% 
 
25. 8B. According to your view, are current regulations in your country effective enough to 
support the use of biomonitoring in occupational health and safety? 
Number of respondents: 26 
 
 
 N Percent 
Yes 6 23,08% 
No, please explain 
why 
18 69,23% 
Do not know 2 7,69% 
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26. 9B. In your country, do you recommend the use of some DNA or protein adduct 
analyses as a marker of exposure in occupational biomonitoring? 
Number of respondents: 26 
 
 
 N Percent 
Yes 7 26,92% 
No 15 57,69% 
Do not know 4 15,39% 
 
27. 10B. In your country, do you recommend the use of some biomarkers of effects 
(including e.g. “omics”-based markers) in occupational biomonitoring? 
Number of respondents: 26 
 
 
 N Percent 
Yes 9 34,62% 
No 13 50% 
Do not know 4 15,38% 
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28. 11B. In your opinion, what are the criteria for using human biomonitoring data in risk 
assessment at workplaces? Please tick all relevant options. 
Number of respondents: 26, selected answers: 109 
 
 
 N Percent 
Existence of validated method for biomonitoring 24 92,31% 
Existence of health based biological limit/guidance values (BLVs/BGVs)* 25 96,15% 
Existence of biological reference (background/normal) values** 19 73,08% 
Biomonitoring levels can be related to the exposure source 22 84,62% 
Biomonitoring level can be directly related to the health effects 18 69,23% 
Other, please specify below 1 3,85% 
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29. 12B. Are biomonitoring results of workers compared to occupational biological limit 
values (BLVs)/biological guidance values (BGVs) or reference values? 
Number of respondents: 26 
 
 
 N Percent 
Yes, to health based BLVs or BGVs 14 53,85% 
Yes, to reference values or population distribution based BGVs 1 3,85% 
Yes, both 9 34,61% 
None of these 2 7,69% 
 
30. 12B.1. Please specify the substances for which there is a BLV or a BGV? You can also 
provide a link to the list of BLVs or attach a list as an attachment. 
Number of respondents: 17 
Responses 
BLVs and BGV in occupational settings 
http://www.irsst.qc.ca/media/documents/PubIRSST/T-03.pdf?v=2017-06-21 
Arsenic, mercury, ethylbenzene, phenol, cadmium, cobalt, chromium(VI), xylene, lead, MOCA, nickel, 
carbon disulphide, styrene, tetrachlorethylene, toluene, trichlorethylene. See "Liite 2" at 
http://julkaisut.valtioneuvosto.fi/handle/10024/79109 
http://www.acgih.org/tlv-bei-guidelines/biological-exposure-indices-introduction 
http://www.acgih.org/tlv-bei-guidelines/biological-exposure-indices-introduction 
See the SCOEL BLV's 
Please follow the link to the law where you can find the information you are looking for: 
https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10009034 
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Responses 
Again a legal document. Sorry, this is not my domain! It could be an attachment to the "Grenzwerte-
Verordnung". But I am not sure! 
PbB 
Binding value: only for lead (transposition of a european directive) - but this value is considered too high 
according to current scientific views 
Pb and Cd are given in stipulations 
See https://www.av.se/arbetsmiljoarbete-och-inspektioner/publikationer/foreskrifter/medicinska-kontroller-
i-arbetslivet-AFS-20056-foreskrifter/?hl=medicinska kontroller 
ww.dol.gov.co.za - hazardous chemical substance - BEI schedule 
BLV for lead only: Lead, 50 ug/dl, blood 
For BGVs see the attached list 
See "Límites de exposición profesional a agentes químicos en España, 2017", page 127 and ff. 
http://www.insht.es/InshtWeb/Contenidos/Documentacion/LEP%20_VALORES%20LIMITE/Valores%20li
mite/LEP%202017.pdf 
The document edited by the INSHT (National Institute of Safety and Hygiene at Work) "Occupational 
Exposure Limits for Chemical Agents in Spain" 
(http://www.insht.es/InshtWeb/Contenidos/Documentacion/LEP%20_VALORES%20LIMITE/Valores%20li
mite/LEP%202017.pdf). 
https://www.ciop.pl 
MAC documentation (full text; PiMOSP) 
BLV (D.Lgs 106/09): Pb blood: 60 µg/100 ml (40 µg/100 ml women<45 years) 
 
31. 12B.2. What is the legal status of these values? 
Number of respondents: 22, selected answers: 30 
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 N Percent 
They are binding limits given by the law. Additional information (optional): 13 59,09% 
They are indicative limit values given by authorities. Additional information 
(optional): 
8 36,36% 
They are recommendations of the laboratory/research institute. Additional 
information (optional): 
9 40,91% 
Other, please specify 0 0% 
 
Answers given into free text field 
Option names Text 
They are recommendations of the 
laboratory/research institute. Additional 
information (optional): 
Additional values are given by the Finnish Institute of 
Occupational Health. see www.ttl.fi/biomonitorointi -&gt; 
Analyysit ja näytteenotto-ohjeet (in Finnish) 
They are recommendations of the 
laboratory/research institute. Additional 
information (optional): 
Finnish Institute of Occupational Health gives 
recommendations of the institute (list of these values not 
given here) 
They are recommendations of the 
laboratory/research institute. Additional 
information (optional): 
Yes, in Biotox a database produce by INRS. 
http://www.inrs.fr/publications/bdd/biotox.html 
They are binding limits given by the law. 
Additional information (optional): 
Only for lead 
They are binding limits given by the law. 
Additional information (optional): 
B-Pb 0,8 &#956;mol/l blood for women below 50 years and 
1,5 &#956;mol/l fro women over 50 yrs. If B-Cd over 50 
nmol/l employee must investigate why and take preventive 
measures, if B-Cd is over 75 nmol/l person is not allowed to 
continue work and exposure to Cd. 
They are binding limits given by the law. 
Additional information (optional): 
lead only 
They are binding limits given by the law. 
Additional information (optional): 
Only for Pb 
They are binding limits given by the law. 
Additional information (optional): 
lead 
They are binding limits given by the law. 
Additional information (optional): 
for lead (Pb) only 
They are binding limits given by the law. 
Additional information (optional): 
only for blood lead 
They are binding limits given by the law. 
Additional information (optional): 
D.Lgs 106/09 
They are indicative limit values given by 
authorities. Additional information 
(optional): 
Concerns the substances listed in question 12B. 
They are indicative limit values given by 
authorities. Additional information 
(optional): 
Biological guidance values listed in the attachment abobe are 
indicative values given by the Ministry of Social Affairs and 
Health 
They are indicative limit values given by 
authorities. Additional information 
(optional): 
In practice, they are applied as a criteria to identify the risk for 
individual workers 
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32. 13B. For the substances for which no BLV or BGV exists for workers, what references 
are used to interpret data (e.g. limit values from other countries)? 
Number of respondents: 19 
Responses 
limit values from other countries 
We usually refer to the booklet of ACGIH, the German DFA or the book Lauwerys. 
No idea. 
If there are no reference values, the biomarker is not used to follow workers 
If there are no reference values, the biomarker is not used to follow workers 
NHANES 
Canada Health Measure Survey 
ACGIH BEI 
DFG BAT 
Do not know 
--- 
usually they are not analysed in the occupational Setting (except in scientific studies) 
When BM is performed, reference values from NIOSH of Germany are used. Laboratories may also give 
reference values, but one should be careful since these values are often for the general population. 
Another source is the Handbook of Lauwerys and Hoet. 
http://www.toxi.ucl.ac.be/documents/mbi.htm: 
ACGIH, SCOEL,DFG, INRS, IRSST, FIOH, LTAP (Louvain centre for Toxicology & Applied 
Pharmacology, UCL) 
ACGIH, BAT, cdc, who 
Limit values from other countries, like USA, European Unión and its Member States 
SCOEl (BLV), ACGIH (BEI), DFG (BAt, EKA, BLW, BAR), FIOH (BAL) 
If there are no references values, the biomarker is not used to follow workers. 
BLV or BGV from other countries 
Literature data about dose-response 
In France, INRS has a website (Biotox) where reference values from other countries or institutions are 
listed (such as SCOEL, ACGIH, DFG, FIOH etc). 
Metals: 
List of recommended health-based biological limit values (BLVs) and biological guidance values (BGVs) 
Scientific Committee on Occupational Exposure Limits (SCOEL) (last update: June 2014): 
BLV Cd in urine: 2 μg/g creatinine 
BLV Pb its inorganic compounds in blood: 30 μg/100 ml  
BLV Hg and inorganic Hg2+ compounds: 10 μg/l in blood, 30 μg/g creatinine in urine  
BGV Ni and Ni compounds in urine: 3 μg/l  
BAT values (DFG): Pb blood 40 µg/100 ml (10 µg/l women<45 years); As urine 50-130 µg/l; Cd urine 15 
µg/l; Co urine 6-300 µg/l; Cr(VI) urine 12-40 µg/l; Ni urine 15-70 µg/l; V urine 35-140 µg/l. 
ACGIH BEIs (end of workweek): As urine 35 µg/g creatinine; Cd urine 5 µg/l; Co urine 15 µg/l and Co 
blood 1 µg/l; Cr(VI) urine 10-25 µg/l; Pb blood 30 µg/100 ml; V urine 50 µg/l. 
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United Kingdom biological monitoring guidance values: Hg urine 20 µmol/mol creatinine (sampling time 
random) 
Pesticides: 
BAT values (DFG): AchE, Lindano in blood and serum; p-nitrophenol in urine 
ACGIH BEIs: AchE, p-nitrophenol in urine, PCP in urine and plasma 
In research projects (case studies) we use limit values from other countries. 
 
33. 14B. Is there work going on to elaborate health based limit values for workers in your 
country? 
Number of respondents: 25 
 
 
 N Percent 
Yes 11 44% 
No 8 32% 
Do not know 6 24% 
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34. 15B. What are the important obstacles you face when applying biomonitoring in 
occupational risk assessment? Please fill in matrix for chemicals in general and 
for the following priority compounds. Notice that the table needs to be scrolled to 
the right to see the rest of the columns! 
Number of respondents: 19, selected answers: 326 
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7,89
% 
   
Human 
biomonit
oring 
level 
cannot 
be 
related 
to 
source 
4 4 3 4 4 1 1 1 1 1 
2
4 
4,0
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35. 16B. How occupational biomonitoring data is usually communicated in your country? 
Tick all options that apply. 
Number of respondents: 25, selected answers: 54 
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 N Percent 
Results are communicated directly to the worker 15 60% 
Results are communicated to the Occupational Health Service 17 68% 
An overview of the results is communicated directly to the employer 11 44% 
Communicated to the national authorities 5 20% 
Other, please specify 4 16% 
Not communicated 2 8% 
 
Answers given into free text field 
Option names Text 
Other, please specify Committee for prevention at work (in a way that medical secret is kept) 
Other, please specify 
An overview of the results is communicated to the employer, providing that 
confidentiality is preserved 
Other, please specify Publications 
Other, please specify The results have to be sent to the ministry of labour 
 
36. 16B.1.  Has occupational health service an obligation to give an overview of the biomonitoring 
results to the employer? 
Number of respondents: 18 
 
 
 N Percent 
Yes 9 50% 
No 5 27,78% 
Do not know 4 22,22% 
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37. 16B.2. Please, elaborate how the results are communicated to the employer (by 
company/plant, by task, are statistical data provided) 
Number of respondents: 9 
Responses 
These is the responsibility of the responsible physician prescribing the analysis. 
Results for the workplace are provided to the employer. Some general statistics are provided. Often 
because many workplaces are small, results are provided related to task or special exposure group or 
time spent near sources of exposures 
The worker receives the result of the examination. The employer only is informed about the date of the 
examination, the ability of the worker to work further with an exposure to the substance in question and 
about the date the next examination has to follow. 
Only statistical data that not can be related to individuals will be reported. 
But only if the employer pays for the report. 
The results have to be used to review the risk assessment and the prevention measures. Care has to be 
taken to report data (to the employer, to the committee for prevention at work) in such a way that the 
medical secret is respected. 
POST SURVEILLANCE AND ANNUAL REPORTS 
I am not aware of the practices but the arrangements vary. 
Individual data are provided directly to employer 
By task with statistical data 
 
 
